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ABSTRACT

DISCOVERY AND CHARACTERIZATION OF NOVEL SUBSTRATE SELECTIVE
INHIBITORS OF HUMAN MRP1 (ABCC1)
ANGELINA SAMPSON
2019
Multidrug resistance protein 1 (MRP1/ABCC1) actively transports a variety of drugs, toxic
molecules and important physiological substrates across the plasma membrane. It can
confer broad-spectrum drug resistance and can decrease the bioavailability of many
important drugs such as anti-cancer agents, antibiotics, antivirals, antidepressants and antiinflammatory drugs. Calcein-AM, a fluorescent reporter commonly used for studying
compound interactions with MRP1 was recently used in the development of a high content
imaging-based assay by our group. This assay was robust and had better sensitivity than
fluorescent plate readouts. The assay identified 12 MRP1 inhibitors after screening an anticancer library of 386 compounds. Due to the multiple distinct substrate binding sites of
MRP1, we sought to use different fluorescent probes to identify substrate selective
inhibitors which were likely missed by the calcein-AM screening. The high content
imaging-based uptake assay was modified using doxorubicin (anticancer drug) and CRO9 (dye) as fluorescent reporters which vary in structure and function. The doxorubicin
assay, after screening the same 386 compound library identified a total of 28 MRP1
inhibitors including 16 inhibitors that have not been previously reported as inhibitors of
MRP1. The CRO-9 assay identified a total of 50 MRP1 inhibitors including 19 additional
inhibitors that have never been reported as inhibitors of MRP1. These 50 MRP1 inhibitors
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included 10 out of 12 hits identified using calcein-AM and 27 out of 28 inhibitors
discovered through the doxorubicin assay. MRP1 inhibition was confirmed using flow
cytometry, confocal microscopy and membrane-based transport assays. Selected drugs
were evaluated for their ability to reverse resistance of MRP1-overexpressing H69AR lung
cancer cells against various substrates. From the doxorubicin screening, mifepristone and
doramapimod were the most effective in reversing MRP1 mediated resistance whiles
celecoxib exhibited selective MRP1 inhibition. From the hits identified through the CRO9-based screening, LY2603618 and ZSTK474 were the most effective in reversing MRP1
mediated resistance in H69AR cells. Together, our findings signify the effectiveness and
value of doxorubicin and CRO-9 based high content screening approach. Anti-cancer
agents that exhibit MRP1 inhibition may be used to reverse multidrug resistance or to
improve the efficacy and reduce the toxicity of various cancer chemotherapies.

1

1.0 Scope of the Study
The significance of this study is to identify novel inhibitors of the multidrug resistance
protein 1 (MRP1) from a unique anticancer library using a high throughput imaging-based
assay with different fluorescent reporters. This chapter explores literature on ATP Binding
Cassette (ABC) transporters, their structure and function, and their role in the development
of multidrug resistance in cancer. The chapter also covers modulators of ABC transporters
and how they can be used for different therapeutic purposes. The literature regarding some
of the common traditional methods used for screening for modulators of key ABC
transporters such as P-gp, MRP1 and BCRP is carefully examined. The chapter then
highlights the literature regarding high content imaging-based assay using fluorescence
reporters, the main technique for the identification of MRP1 inhibitors. The chapter finally
concludes by looking at the rationale of the current study and importance of profiling drug
interaction with ABC transporters. It also addresses potential utilization of our findings in
overcoming multidrug resistance.

1.1 Introduction to ABC transporters
ABC transporters represent a large evolutionarily conserved superfamily of membrane
proteins ubiquitous in practically all living organisms. In the human genome, a total of 48
ABC transporter genes have been identified and are classified into seven subfamilies,
designated A to G (Figure 1.1) according to sequence homology and structural organization
[1].
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Figure 1.1 Classification of ABC transporter family genes identified in the human genome

Most ABC transporters can shuttle endogenous molecules and xenobiotics across
membranes. ABC transporters play a role in physiological functions such as tissue defense
against exogenous molecules and maintenance of balance between antioxidant and free
radical concentrations (the MRPs), detoxification (P-gp), absorptive and secretory
activities (ABCBs and MRPs), antigen presentations (ABCB2 and ABCB3) and lipid
metabolism (ABCA1 and ABCGs) [2]. ABC transporters also play a role in the transport
of various physiological substrates such as amino acids, peptides, lipids, and inorganic
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ions. The importance of ABC transporters is highlighted by the fact that mutations in
various ABC transporter genes are associated with human diseases. These diseases include
cystic fibrosis (ABCC7), Dubin-Johnson syndrome (ABCC2), gout (ABCG2), intrahepatic
cholestasis (ABCB4), schizophrenia (ABCA13), sitosterolemia (ABCG5 and ABCG8),
Tangier disease (ABCA1), surfactant metabolism syndrome (ABCA3), Harlequin-type
ichthyosis (ABCA12), inflammatory bowel disease (ABCB1), and adrenoleukodystrophy
(ABCD1) [2,3]. Nine ABC transporters are associated with drug resistance due to their
ability to efflux xenobiotics with majority from the ABCC subfamily These are Pglycoprotein (P-gp/ABCB1), Multidrug resistance proteins (MRP1-MRP7), and breast
cancer resistance protein (BCRP/ABCG2) [5]. Accumulating evidence has indicated a key
role of these transporters in governing the transit of both endogenous and drugs substrates
and their metabolites across major organs and physiological barriers (Figure 1. 2) such as
liver, kidney, blood-brain barrier, blood-testis barrier, and non-polarized cells [5, 6]. The
cystic fibrosis transmembrane conductance regulator (CFTR/ABCC7) and sulfonyl urea
receptor (SUR, ABCC8) are ATP-dependent protein channels but do not directly transport
drugs [8]. ABC transporters that efflux drugs such as P-gp, MRP1 and BCRP are known
to affect drug efficacy and toxicity [8, 9]. Thus, it is essential to assess their interactions
with new drugs in the drug discovery and development process.
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Figure 1.2 Localization of ABC transporters at four pharmacological barriers
Top: blood-brain barrier; mid-left: hepatocyte; mid-right: proximal tubule cell; enterocyte)
[10, 11, 12]. Arrows indicate the direction of transport. Common name of transporters is
shown.

1.2 Structure and function of ABC transporters
ABC transporters efflux specific substrates across cell membranes against a concentration
gradient using energy derived from ATP binding and hydrolysis. The general structure of
ABC transporters comprises of nucleotide binding domains (NBD) located on the
cytoplasmic side of the membrane and two sets of membrane spanning domains (MSD).
The NBDs of all ABC transporters have 3 conserved motifs; Walker A, B and C. Walker
A and Walker B motifs are essential for ATP- binding and hydrolysis reactions [14]. The
Walker A motif binds to the α- and γ- phosphates of di- or tri- nucleotides whiles Walker
B motif helps manage magnesium ions. Walker C (LSGGQ) is a signature to ABCtransporters and has been proposed to play a role in the dimerization of NDB1 and NDB2
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[15]. Each MSD contains six transmembrane spanning α-helices [13, 6] which form
substrate translocation pathway. ABC transporters with at least two MSDs and two NBDs
are considered full transporters whereas those with one of each domain are known as half
transporters [17]. MRPs with a four-domain arrangement of two MSDs and two NBDs are
known as ‘short MRPs’, whiles ABC transporters with an additional NH2-proximal MSD0
are referred to as ‘long MRPs’ [18] (Figure 1.3).

A

B

Figure 1.3 The predicted topology of long and short MRPs
Protein backbone is illustrated as thin tubes while transmembrane helices are shown as
cylinders. A. The predicted topology of the MSDs and NBDs of long MRPs (MRP1, 2, 3,
6, and 7). B. The predicted arrangement of short MRPs (MRP4, 5, 8, and 9). [18]
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MRP1 has an extra MSD (MSD0) towards the N terminus and comprises of 5 additional
transmembrane spanning α-helices located on the extracellular side of the membrane.
MSD0 does not play a role in the efflux activity of the transporter, but it is required for
efficient retention of MRP1 at the cell surface [19]. The NBDs are directly involved in the
binding and hydrolysis of ATP [20]. The MSDs provide substrate binding sites and
contribute to transporter specificity [15, 16]. The binding site of MRP1 is bipartite in
nature; a positive charged region that binds to GSH moiety (P-pocket) and a large
hydrophobic area that encompass a lipid tail (H pocket) [23]. This nature enables it to bind
to a more diverse nature of compounds which ae structurally unrelated.
The proposed transport mechanism for substrate transport is the ATP switch model by
Higgon and Linton [22]. According to this model, the NBDs of MRP1 alternate between a
closed and an open conformation. These movements result in ligand translocation [24].
The closed conformation has two ATP molecules bound to the NBD dimer interface
forming a nucleotide pocket. In the pocket, ATP binds to the Walker A and Walker B
motifs. Transport is initiated by the binding of substrate to the MSDs in the open NBD
conformation which increases affinity to ATP [16, 18]. The binding of ATP induces
changes in the formation of closed NBDs dimer which subsequently induces a major
conformational change in the MSDs to start substrate transport. ATP hydrolysis occurs
which causes changes in the NBD dimer dissolution to be transmitted to the MSDs. The
basal state of transporter is restored with sequential release of inorganic phosphate and
adenosine diphosphate (ADP) [16, 19]. This substrate transport mechanism was confirmed
in studies on the binding of LTC4 (MRP1 substrate) to bovine MRP1 (91% identical to
human MRP1). The binding of LTC4 was shown to bring the NBDs closer and aligned
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properly. ATP hydrolysis occurs when the two NBDs dimerize to form a complete catalytic
site. The binding of LTC4 stabilizes the closed conformation where NDBs are properly
aligned [17, 20].

1.3 Multidrug resistance in cancer
Multidrug resistance (MDR) is the resistance of cancer cells to multiple chemotherapeutic
agents with different structures, targets and mechanism of action. MDR mechanisms can
be categorized into 7 areas as shown in Figure 1.4. These areas include; (1)increased drug
efflux by membrane transporters (mainly, ABC transporters); (2) reduction in drug uptake
by influx transporters (solute carriers); (3) enhanced drug metabolism; (4) blocking
apoptotic signaling pathways; (5) Gene regulation; (6) mutation in drug targets or feedback
activation of other targets and signaling pathways; and (7) chemoresistance induced by
changes in the microenvironment. However, one of the most common mechanism studied
is increased drug efflux due to the overexpression of ABC transporters [21, 22].
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Figure 1.4 Mechanisms of Multidrug resistance in cancer
[29]

The most studied MDR transporters include P-gp, MRP1 and BCRP [30]. The
overexpression of these transporters leads to efflux chemotherapeutic agents thereby
reducing drug accumulation and causing tumor cells to become resistant. The specific
association between membrane transporters and multidrug resistant phenotype was first
discovered in the Chinese hamster ovary cell line in the 1970s. This cell line selected for
resistance to colchicine, was found to also exhibited resistance to daunomycin and
puromycin [31]. P-gp, a 170 kDa glycoprotein, regulates the export of a wide variety of
anticancer drugs and other hydrophobic compounds including anthracyclines (doxorubicin,
daunorubicin), epipodophyllotoxins (etoposide, teniposide), vinca alkaloids (vincristine,
vinblastine), taxanes and the cancer imaging agent tetraphenylphosphonium (TPP) [32].
Intravenous administered drugs such digoxin, cyclosporine, ivermectin, paclitaxel,
vinblastine, grepafloxacin, indinavir and nelfinavir also undergo intestinal excretion
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mediated by P-gp. P-gp is expressed in normal tissues, such as the epithelium of the
kidneys, liver, intestine, pancreas, placenta and adrenal gland, where it excretes toxic
metabolites [33]. It is also located at the apical, mucosal and lumenal surface of epithelial
cells in organs often involved in drug absorption, distribution and excretion [34]. Literature
has shown that tumors originating from tissues with naturally high levels of P-gp
expression may be intrinsically drug resistant (e.g., colon, kidney, pancreas, and liver
carcinoma) [34]. Several studies have reported the presence of P-gp mRNA and protein in
clinical samples cancers such as leukemia, kidney, colon, breast, and lung cancers [31,32].
The elevated expression of P-gp has been linked to poor response to chemotherapy.
MRP1, a 190 kDa protein, was first discovered in an anthracycline-resistant cell line
HL60/Adr [37]. Unlike P-gp, MRP1 is localized at the basolateral membrane of epithelial
cell layers [68], and thus, it transports substrates towards the basolateral side of the
epithelia. A significant number of drug substrates of P-gp overlaps with MRP1. MRP1
confers resistance to a wide range of anticancer drugs such as anthracyclines, vinca
alkaloids, epipodophyllotoxins, camptothecins, methotrexate (MTX), saquinavir, and
mitoxantrone (MX); however, in contrast to P-gp, it does not confer resistance to taxanes.
Taxanes are an important component of the P-gp resistance profile. Although the drug
resistance profile of MRP1 and P-gp overlaps, their physiological substrate profile differs
significantly. While substrates for P-gp are neutral or mildly positive lipophilic
compounds, MRP1 can efflux of a broad array of physiological organic anions such as
leukotriene C4 (LTC4) and dinitrophenyl-S-glutathione (DNP-SG) [19]. The discovery that
MRP1 was capable of transporting both conjugated and non-conjugated organic anions
broadened it pharmacological and physiological relevance. Conjugated xenobiotic organic
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anions which are produced from phase II metabolism of drugs and GSH conjugated drugs
are also effluxed by MRP1. It can also transport glucuronate conjugates (e.g., E217βG),
dianionic bile salts, and sulfate conjugates [28].
Clinically, MRP1 has been found to be up-regulated in a variety of solid tumors, including
those of lung, breast, and prostate [32]. Its expression is a negative prognostic marker for
early-stage breast cancer [38] and predicts poor response to chemotherapy and decreased
survival in non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC)
[28, 29]. NSCLC forms majority of lung cancer cases and the disease is commonly
aggressive and chemo-resistant. Interestingly, MRP1 is found to be frequently
overexpressed in a large percentage of tumors prior to treatment and in the case of prostate
cancer, the MRP1 levels is known to increase with disease progression [40]. The most
compelling case for the clinical role of MRP1 in multidrug resistance is the case of
neuroblastoma where there is a strong association of MRP1 with a negative clinical
outcome. A retrospective study showed that MRP1 expression was found in 209
neuroblastoma samples. Multivariate analysis revealed that an increased MRP1 expression
was highly predictive of a lower relapse free survival and the overall survival of patients
[41]. The study provided evidence of MRP1 as a strong independent prognostic indicator
in neuroblastoma. Interestingly, P-gp/ABCB1, expression did not predict clinical outcome
[41]. This suggests that MRP1, not P-gp, is the primary mode of MDR in neuroblastoma.
BCRP, a (70 kDa) consisting of a single NBD and MSD, functions as either homodimers
or homomultimers bridged by disulfide bonds. It was first cloned based on its
overexpression in a doxorubicin-resistant MCF7 breast cancer cell line (MCF-7/AdrVp).
BCRP expression is varied among normal tissues with the highest levels found in the
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placenta. It is also prominently expressed on the apical membrane of the epithelium in the
small intestine and colon and on the canalicular membrane of hepatocytes [42]. BCRP can
mediate efflux of doxorubicin, mitoxantrone, topotecan, irinotecan and it active metabolite
SN38, methotrexate, and tyrosine kinase inhibitors. In addition to hydrophobic substrates
such as mitoxantrone, BCRP can also transport hydrophilic conjugated organic anions like
the sulfate conjugates unlike P-gp [43]. BCRP has been found to be overexpressed in
several tumors, however majority of work has been in the area of acute myeloid leukemia
(AML). Several studies have shown a positive correlation between high levels of BCRP
expression and poor clinical outcomes in AML, e.g., a relapsed or refractory disease state,
lower response rate, shorter overall survival, and/or no complete remission. Other studies
reported no correlation of BCRP expression with clinical outcomes or no expression of
BCRP in AML. Factors such as low sensitivity of methods used and the co-expression with
P-gp and MRP1 in patients with AML has been attributed as the possible reasons of the
disparities in literature [44].
Several in vitro studied have demonstrated that TKIs such as imatinib, nilotinib, and
dasatinib are modulators of P-gp and BCRP [45]. Clinical studies have also shown a
correlation between mRNA expression of P-gp and BCRP in peripheral blood leukocytes
and poor clinical outcomes in 118 chronic-phase CML patients receiving a standard dose
of imatinib mesylate [46]. BCRP mRNA expression levels were higher in patients who did
not respond to treatment before and during imatinib therapy. These data suggest that the
elevated expression of BCRP may be associated with imatinib resistance.
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1.4 Modulators of ABC transporters
Ligands which interact with ABC transporters can act as substrates (effluxed by
transporter), inhibitor (impairs transport of other compounds), inducers (enhance
transporter protein expression) or activators (enhance transporter activity). The different
properties and modes of action can be explored for diverse therapeutic use. Inducers and
activators are not always related as an increase in protein expression may not induce
increased protein activity [17]. Whiles inducers promote upregulation of transporter,
activators induce conformational changes which stimulates the transport/efflux of a
substrate bound to another binding site. Both inducers and activators can be useful in
conditions where toxicity to target tissues can be reduced due to transporter overexpression.
Dexamethasone [47], rifampicin [47], sunlinac [48], vinblastine and TBHQ are all inducers
of MRP1[49]. A compound can have overlapping modes of action. Some substrates can
act as inhibitors. Generally, it has been much more difficult to find good small molecule
inhibitors for MRP1 than for P-gp. This may be due to MRP1’s preference for anionic
compounds as substrates or inhibitors. Most anionic compounds enter cells poorly, thus it
may be difficult to obtain good intracellular concentrations to aid effective inhibition. A
variety of inhibitors of MRP1 have been identified including the LTC4 analogue MK571,
S-decylglutathione, sulfinpyrazone, benzbromarone and probenecid [13, 34, 35]. For
specific MRP1 in vivo inhibition, general organic anion transporter inhibitors such as
sulfinpyrazone, benzbromarone and probenecid are not suitable, as they affect organic
anion uptake systems in cells. The main challenges with these inhibitors are their broad
range specificity and cytotoxicity. In order to overcome MRP1 mediated resistance in
cancer chemotherapy, better MRP1 inhibitors need to be developed, with higher
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specificity, cellular penetration properties, and low cytotoxicity. The scope of this study
focuses mainly on identifying inhibitors of MRP1. This work seeks to provide
methodological alternatives to identify MRP1 inhibitors using high throughput screening
based on high content imaging.

1.5 In vitro screening methods for evaluating ABC transporter interaction
Determination of a drug candidate as an inhibitor/substrate of ABC transporters is vital in
profiling drug-transporter interactions as it helps predict the drug candidate’s
bioavailability in vivo. Drugs and food nutrients that modulate ABC transporters may also
affect the bioavailability of a co-administered drug. Generally, in vitro assays are
categorized as ‘cell-based’ or ‘membrane-based’ depending on whether an assay is
performed with intact cells or with isolated membranes [51]. Both cell and membranebased assays are riddled with their intricate advantages and disadvantages and are
frequently performed together to verify and validate data derived from each other. Several
in vitro assays have been developed to probe the interactions between drug candidates and
these efflux transporters. ABC transporters are also well known to have a broad range of
substrate specificity, due to the existence of multiple substrate binding sites. Thus, assay
systems that utilize a single probe compound may not identify all substrates or modulators
that bind at different binding sites resulting in false negatives. Cost reduction, effective
prediction of drug-transporter interaction in vivo, and toxicity are areas that need
improvement in the current systems used. In the following sections, some common in vitro
assay for studying drug -transporter interactions relevant to this study are discussed.
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1.5.1 Fluorescence accumulation and efflux assay
One of the most widely used cell-based assays for assessment of compound interaction
with ABC transporters is the fluorescent accumulation assay. This assay measures the
intracellular accumulation of a fluorescent substrate in a transporter-overexpressing cell
line in the presence or absence of test compounds in order to understand the effect of test
compounds on transporter activity. The intracellular accumulation of the fluorescent
substrates is inversely proportional to the transporter activity and can be measured by
fluorescence spectrophotometry. Thus, an increased intracellular accumulation of a given
substrate (higher intracellular fluorescence) can be observed in the presence of an inhibitor,
while the opposite (decreased intracellular accumulation) occurs in the presence of an
inducer or activator. Discrimination between an inducer or activator is dependent on the
incubation period with the test compounds. Activators need lesser time period to elicit their
effect as they only induce conformational changes whiles inducer need extended incubation
time period with drugs as de novo synthesis of transporter is needed. Generally, assays
using a fluorescent probe to track transporter activity are also termed the dye extrusion
assay or the uptake assay [52].
In efflux studies, however, the amount of fluorescent substrate in the extracellular
environment of cells is measured under various conditions known to influence the
transporter activity. Cells are preloaded with the substrate of interest in the presence of an
inhibitor of the efflux transporter, the amount of fluorescent substrate expelled from the
cells will be less than that observed for cells without inhibitor. In contrast, the amount of
fluorescent substrate expelled will be greater in the presence of an inducer or activator.
This method is thus based on the altered accumulation and efflux of a fluorescent substrate.
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The analysis of the efflux activity of transporters may be based on the evaluation of the
fluorescence accumulation, efflux or both.
Table 1.1 shows a list of common fluorescent substrates used for studying drug transporter
interactions. Detection and quantification of the intracellular accumulated fluorescent
substrate is commonly determined by flow cytometry. Quantitative measurements of the
differences in fluorescence levels between non-treated control and drug treatments are thus
used for inferences and analysis. Therefore, test compound that exhibit inherent
fluorescence at the emission similar to that of the fluorescent substrate used can interfere
with quantification. As such, it is important to inspect the background fluorescence of
individual test compounds.
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Table 1.1 Fluorescent substrates for ABC transporter assays
ABCB1
(Pgp)
Fluorescent probe
Green/FITC
BODIPY FL EDA
BODIPY FL Forskolin
BODIPY FL Histamine
BODIPY FL Prazosin
BODIPY FL Thapsigargin
BODIPY FL Verapamil, HCl
BODIPY FL Vinblastine
Calcein AM
CBIC2(3) (JC-1)
DiNOC1(3) (JC-9)
DiOC2(3)
DiOC5(3)
DiOC6(3)
eFluxx-ID Green
ER-Tracker Green
MitoTracker Green FM
Phengreen diacetate
Rhodamine 123
SYTO 13
SYTO 16
SYTO 9
Yellow/PE
Alexa Flour 555 hydrazide
Alexa Fluor 532, 594, 546 C5maleimide
CellTracker Orange CMTMR
eFluxx-ID Gold
MitoTracker Orange CMTMRos
Rhodamine 6G chloride
Rhodamine B, hexyl ester,
perchlorate (R6)
TMRE
Red
DiIC1(5)
Doxorubicin
Mitoxantrone
Pheophobide A
DAPI/ Blue
Dyecycle violet (DCV)
Orange
Tetramethylrosamine Chloride

ABCC1
(MRP1)

ABCG2
(BCRP)

REFERENCES

[53]
[53]
[53]
[54]
[53]
[53]
[55],
[56], [57]
[58], [59],
[53]
[60]
[53]
[61]
[62]
[53]
[53]
[63]
[57], [64]
[53]
[53]
[53]
[53]
[61]
[53]
[62]
[53]
[53]
[53]
[53]
[53]
[65], [66], [60]
[67], [66]
[68], [69]
[70], [63]
[71], [53]
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1.6 Traditional membrane-based assays
1.6.1 Inside-out Membrane Vesicles
Membrane vesicles prepared from cells expressing ABC transporters are a valuable tool
for studying ABC transporter activities. Membrane vesicle preparation exposes the
substrate-binding site of ABC transporters and allows better identification of certain classes
of compounds due to matrix simplification of the vesicles. Membrane vesicles can be
prepared from various sources such as intestinal brush border membranes, hepatic
sinusoidal and canalicular membranes, encephalic luminal and abluminal membranes, and
any transporter-expressing cell lines[72]. Cell lines engineered to overexpress individual
transporters are especially useful for the evaluation of specific interactions between the
transporter and compounds of interest. Vesicular transport studies using various types of
membranes from different sources (insect cells [10], transfected [73] or selected [74]
mammalian cell lines and artificial membrane vesicles [75] have been reported.
Mammalian HEK293 and insect Sf9 membrane vesicles expressing ABC transporters are
widely used as a screening tool in drug discovery [10] and are commercially available. The
preparation of membrane vesicles involves the disruption of cells or tissues and the
collection of the membrane fraction through ultracentrifugation. Three types of membrane
formations can exist in a crude membrane preparation: lamellar, inside-out, and right-sideout (Figure 1.5) [73].
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Figure 1.5 Various orientation of crude membrane vesicle
A. Membrane vesicles formed inside-out. Further enrichment of crude membrane vesicle
can increase their percentage. B. Membrane vesicles in open lamellar configuration. C.
Membrane vesicles in right side-out configuration.

In the membrane vesicular transport assay investigating efflux transporters, only inside-out
vesicles contribute to the trapping of target substrates, so it is desirable to enrich vesicles
with the inside-out orientation. Traditionally, low ionic strength buffer devoid of bivalent
ions has been used to achieve this. Nitrogen cavitation is another feasible method for
promoting the formation of inside-out vesicles in the crude membrane preparation [57, 9].
Purification of crude membrane using methods such as sucrose gradient centrifugation [58,
59] and concanavalin-A chromatography [75] can further enrich the concentration of
inside-out vesicles [73]. Once the membrane vesicles are generated, they are relatively
stable and can be stored at -80 °C for many months [73]. Membrane vesicles are also ideal
for studying ABC transporter kinetics.
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1.6.2 Membrane vesicular transport
The membrane vesicular transport assay is based on the ATP-dependent transport of a
substrate into the inside-out membrane vesicles. It was the first in vitro assay developed
for ABC transporter studies when Horio et al. used membrane vesicles prepared from a
cancer cell line to detect the ATP-dependent transport of vinblastine by ABCB1 [76]. To
date, it is commonly employed for the determination of transporter substrates and
inhibitors, especially in a high throughput format [59, 42]. Recently, this assay has been
coupled with targeted metabolomics for the identification of endogenous ABC transporter
substrates present in bodily fluids, a novel approach termed ‘transportomics’ [62, 41].
Functionally, the membrane vesicular transport assay can be performed in a ‘direct’ or an
‘indirect’ (inhibition) setup [51]. In the direct setup, the transport of a compound of interest
into the membrane vesicles is measured directly, enabling the identification of a substratetype relationship with a given transporter. This setup, however, requires each test
compound to be labeled or analyzed with sensitive analytic methods such as LC-MS/MS,
making it rather costly for screening purposes. Furthermore, the direct setup is not robust
in terms of identifying substrates with medium-to-high membrane permeability as they
diffuse out of the membrane vesicles, resulting in false negative hits [72]. As a result, the
direct setup is typically used for studying transport of compounds with low membrane
permeability such as methotrexate, bile acids, and sulfate and glucuronide conjugates of
various phytoestrogens [62, 41, 63, 64, 65, 66]. The indirect setup, on the other hand,
examines the inhibitory effect of a test compound on the transport of a reporter substrate.
Because only the reporter substrate needs to be labeled and/or analyzed, the indirect setup
is well-suited for high throughput screening of compound-transporter interactions. As a
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caveat, this setup will not provide information on whether the test compound is a substrate
of the transporter being studied.
The quantity of the transported unlabeled molecules can be determined by HPLC, LC/MS,
LC/MS/MS. Alternatively, the compounds are radiolabeled, fluorescent in nature or have
a fluorescent tag so that the radioactivity or fluorescence retained on the filter can be
quantified. Table 1.2 gives a list of common radiolabeled substrates used for transporter
studies.
The vesicular transport assay can also be performed in an "indirect" set-up, where
interacting test drugs modulate the transport rate of a reporter compound [53]. This assay
type is particularly suitable for the detection of possible drug-drug interactions and drugendogenous substrate interactions. This assay format is not sensitive to the passive
permeability of the compounds and therefore detects all interacting compounds. However,
being an indirect method, it will not give information on whether the compound tested is
an inhibitor of the transporter or a substrate of the transporter inhibiting its function in a
competitive fashion.

21

Table 1.2 Commonly used radiolabeled substrates for transport assays
Radiolabeled substrate

TRANSPORTER

REFERENCES

[14C]-1-Chloro-2,4-Dinitrobenzene ([14C]-) (CDNB)

MRP1, MRP2

[80],

[14C]-2-Amino-1-Methyl-6-Phenylimidazo[4,5-b] Pyridine ([14C]-

BCRP, MRP2

[82]

[3’,5’,7’-3H(n)]-Methotrexate

MRP2, MRP4

[83]

[3H] Estradiol 17-(β-d-Glucuronide) ([3H]-E217βG)

BCRP

[51]

[3H]-Daunorubicin

P-gp, MRP1

[84]

[3H]-Docetaxel

MRP2

[85]

[3H]-Etoposide

MRP2, BCRP

[86], [87]

[3H]-Leukotriene C4 ([3H]-LTC4)

MRP1

[81]

[3H]-Methotrexate

BCRP

[79]

[3H]-Mitoxantrone

BCRP

[79]

[3H]-Paclitaxel

P-gp, MRP2

[61], [88]

[3H]-Vinblastine

MRP2

[88]

[6,7-3H] Estradiol 17-(β-d-Glucuronide) ([3H]-E217βG)

MRP1, MRP2,

[88], [89]

PhIP)

MRP3, MRP4
[7-methoxy-3H]-Prazosin

BCRP

[90]

[G-3H]-Digoxin

P-gp

[57]

[G-3H]-Vinblastine Sulfate

P-gp

[91]

[ring C, methoxy-3H]-Colchicine

P-gp

[57]

1.7 Current/alternate methods for assessment of compound interactions
Relatively new assays are currently available for high-throughput screening of compound
interaction with ABC transporters. Although not as widely used, they offer unique
advantages over the abovementioned traditional assay systems. Some of these new assays
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include high content imaging, bioluminescent imaging, fluorescence resonance energy
transfer (FRET), and antibody binding shift assay. For the scope of this study we will focus
mainly on high content imaging.

1.7.1 High Content Imaging
In recent years, imaging-based high content screening (HCS) using an automated
microscope platform has gained increasing popularity in drug discovery and biomedical
research. HCS allows high-throughput imaging of single or multiple biological activities
measured as intensity or spatial localization of fluorescent dyes or proteins in cells or whole
organisms. HCS platform offers unique advantages over traditional high throughput
screening (HTS). The major advantage is the ability to provide multiple readouts. The
readout is typically a fixed endpoint based on object segmentation, which minimizes
background noise and facilitates automated analysis.
HCS methods have been used to investigate compound interactions with P-gp and BCRP.
Ansbro et al. screened a kinase inhibitor library for P-gp inhibitory activity with an uptake
assay using multidrug-resistant P-gp-overexpressing KB-V1 carcinoma cells and the
parental KB-3-1 cells with calcein AM as the fluorescent probe [92]. Phase-contrast and
fluorescent images were acquired which allowed for segmentation masks. This helped
identify individual cells constructed based on phase-contrast images and used for the
quantification of intracellular fluorescence intensity[92]. Using the HCS platform, several
P-gp modulators were identified. The assay also provides greater sensitivity over plate
reader, which is more suitable for homogeneous assay. We recently set up an uptake assay
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for studying compound interaction with MRP1 using a similar method [93]. Example for
cell segmentation is shown in Figure 1.5. An additional, advantage of HCS is that unlike
assays using a flow cytometer, cells can be imaged in situ without the need of preparing
cell suspension and performing multiple washing steps, which increase the processing time
and limit the assay throughput. Furthermore, cell viability and density before and after
treatment can be visually inspected in bright-field or phase-contrast images. This assists in
the evaluation of compound cytotoxicity, which may interfere with the assay.

Figure 1.6 Example of high content images and segmentation
[93]

The examples discussed above improve the sensitivity and processing time of traditional
uptake assay. However, HCS platform can offer additional analysis capability studying
multiple functions simultaneously. In a recent study conducted by Antczak et al., an HCS
platform was used to simultaneously investigate BCRP-inhibitory and cytotoxicity of test
compounds [94]. Using human glioblastoma cell line U87MG stably expressing BCRP,
uptake of a fluorescent BCRP substrate, JC-1 (J-aggregate–forming lipophilic cation
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5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethyl benzimidazole carbocyanine iodide), after a 16-h
incubation was used to probe compound inhibition of BCRP, while Hoechst accumulation
in the nuclei was used to reflect cell number, which indicates cytotoxicity of test
compounds.

1.8 Rationale of Study
ABC transporters are involved with the uptake of small molecules thus recognized as the
key drug transporters for assessment in the drug discovery and development process. This
recommendation was made by the International Transporter Consortium (ITC), a team of
experts in pharmacology and pharmaceutical sciences from academia, industry, and the US
Food and Drug Administration (FDA) in 2007 [10]. Currently, recommendations for the
appropriate in vitro and in vivo studies for drug-transporter interaction are only available
for ABCB1 (MDR1) and ABCG2 (BCRP) [60]. We anticipate that with an increased
appreciation for the relevance of ABC transporters, interactions between drug candidates
and ABC transporters will become a routine assessment.
Drug discovery and development is an intricate, time-consuming, and costly process. The
cost of successfully developing an approved drug from a new molecular entity (NME) is
estimated to be between $800 million and $1.2 billion, with a development timeline of 8–
12 years [95]. Between 2007 and 2010, the combined success rate at Phase III clinical trial
and submission fell to approximately 50%, with major causes of attrition being lack of
efficacy and safety issues [96]. In Phase II clinical trials, apart from strategic failures, lack
of efficacy, safety issues, and unfavorable bioavailability are reasons drug candidates fail
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[97]. As the key efflux transporters regulating the absorption, distribution, metabolism,
excretion, and toxicity (ADMET) of xenobiotics, ABC transporters can influence the
bioavailability and toxicity of a substrate drug through direct efflux, drug-drug and drugnutrient interaction (DDI and DNI) [10], [98]. Efflux by ABC transporters in organs such
as intestines, livers, and target organs can limit the bioavailability of drugs, resulting in
sub-therapeutic concentrations of drugs [98]. Conversely, the efflux activity of ABC
transporters can be crucial in liver toxicity [98]. Considering the importance of ABC
transporters in determining drug absorption, disposition, and toxicity, there is a need for
profiling the interactions of leading drug candidates with ABC transporters.
Developing high content screening assays for ABC transporters may provide an effective
pathway against drug-induced toxicity. With new test compounds and pharmacological
libraries being developed against a wide range of diseases, it is important to develop
screening methods with high specificity and reliability for identifying modulators of ABC
transporters especially for transporters that are implicated in multidrug resistance
phenotype (P-gp, MRP1, and BCRP). The use of just one traditional in vitro screening
method is fraught with challenges such as the possibility of false negative results because
of the relatively low sensitivity of these methods.
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Doxorubicin as a Fluorescent Reporter Identifies Novel MRP1 (ABCC1) Inhibitors
Missed by Calcein-Based High Content Screening of Anticancer Agents

Abstract
Multidrug resistance protein 1 (MRP1/ABCC1) actively transports a variety of drugs, toxic
molecules and important physiological substrates across the plasma membrane. It can
confer broad-spectrum multidrug resistance and can decrease the bioavailability of many
important drugs. Substrates of MRP1 include anti-cancer agents, antibiotics, antivirals,
antidepressants and anti-inflammatory drugs. Using calcein as a fluorescent reporter in a
high content efflux assay, we recently reported the identification of 12 MRP1 inhibitors
after screening an anti-cancer library of 386 compounds. Here, we describe the
development of a new high content imaging-based efflux assay using doxorubicin as a
fluorescent reporter. Screening the same anti-cancer library of 386 compounds, the new
assay identified a total of 28 MRP1 inhibitors including 16 inhibitors that have not been
previously reported as inhibitors of MRP1. Inhibition of MRP1 activity was confirmed
using flow cytometry, confocal microscopy and membrane vesicle-based transport assays.
Six drugs (afatinib, celecoxib, doramapimod, mifepristone, MK-2206 and rosiglitazone)
were evaluated for their ability to reverse resistance of MRP1-overexpressing H69AR lung
cancer cells against vincristine, doxorubicin and etoposide. Mifepristone and doramapimod
were most effective in reversal of resistance against vincristine while mifepristone and
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rosiglitazone were most successful in resensitizing H69AR cells against doxorubicin.
Furthermore, resistance towards etoposide was completely reversed in the presence of
celecoxib or doramapimod. Selected drugs were also evaluated for resistance reversal in
HEK cells that overexpress P-glycoprotein or breast cancer resistance protein. Our results
indicate mifepristone and doramapimod as pan inhibitors of these three drug transporters
while celecoxib exhibited selective MRP1 inhibition. Together, our findings signify the
importance of MRP1 in drug discovery and demonstrate the effectiveness and value of
doxorubicin-based high content screening approach. Anti-cancer agents that exhibit MRP1
inhibition may be used to reverse multidrug resistance or to improve the efficacy and
reduce the toxicity of various cancer chemotherapies. On the other hand, anti-cancer drugs
which did not interact with MRP1 carry low risk for developing MRP1-mediated
resistance.

Keywords: MRP1; ABCC1; ABC transporter; multidrug resistance; MRP1 inhibitors; drug
absorption and disposition; high content screening; anti-cancer agent; drug-transporter
interactions; doxorubicin; drug profiling
1) Afatinib (PubChem CID: 10184653); 2) Alisertib (PubChem CID: 24771867); 3)
Alvespimycin (PubChem CID: 5288674);; 4) Amuvatinib (PubChem CID: 11282283); 5)
Celecoxib (PubChem CID: 2662); 6) Doramapimod (PubChem CID: 156422); 7)
Flavopiridol (PubChem CID: 5287969); 8) GSK2126458 (PubChem CID: 25167777); 9)
GSK461364 (PubChem CID: 15983966); 10) GW4064 (PubChem CID: 9893571); 11)
LY2228820 (PubChem CID: 11570805); 12) LY294002 (PubChem CID: 3973); 13)
Mifepristone (PubChem CID: 55245); 14) MK-2206 (PubChem CID: 24964624); 15)
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NVP-BSK805 (PubChem CID: 57339395); 16) OSI-420 (PubChem CID: 18924996); 17)
Rosiglitazone (PubChem CID: 77999); 18) Saracatinib (PubChem CID: 10302451)
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1.0 Introduction
Cancer is the second leading cause of death worldwide with 8.8 million deaths occurring
in 2015 and an estimated 20 million new cases expected annually till 2025 [1, 2].
Combinatorial therapeutic approach of using multiple cytotoxic drugs for cancer treatments
has led to improvements in survival rates for various types of cancers [3] . However, the
emergence of drug resistance in tumor cells in many cancers over the years have been a
challenge to treatment. Tumor cells when exposed to cytotoxic drugs can develop crossresistance to a wide range of compounds [4, 5]. This phenomenon, known as multidrug
resistance (MDR) makes tumors unresponsive to a variety of drugs irrespective of their
differences in structure and molecular targets [3] and can lead to failure in chemotherapy.
Conventional chemotherapeutic drugs such as doxorubicin, vincristine, actinomycin-D,
and paclitaxel have been previously shown to induce MDR [6].
Development of resistance is a major obstacle in the success of chemotherapy. MDR is
reportedly responsible for over 90% of chemotherapy failures of metastatic cancers
involving surgery or radiation [7]. MDR can be acquired through various mechanisms such
as alteration of drug target, decreased drug absorption, increased drug efflux, increased cell
repair activity, alteration in lipid membrane composition and altered cell cycle check points
[3, 7]. However, the overexpression of ATP-binding cassette (ABC) drug efflux
transporters is the most frequent mechanism of MDR and is widely studied [3, 8, 9, 10]. A
total of 48 ABC transporter genes have been reported in the human genome and they are
grouped into seven subfamilies, designated A-G [11]. In particular, ABC drug transporter
proteins such as P-glycoprotein (P-gp/ABCB1), multidrug resistance protein 1
(MRP1/ABCC1) and breast cancer resistance protein (BCRP/ABCG2) are frequently
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upregulated in cancer [12, 13]. These drug transporters actively pump out
chemotherapeutic drugs reducing the intracellular levels of drugs and thereby attenuating
their cytotoxic actions.
The prototypical eukaryotic ABC proteins have a four-domain core structure, containing
two hydrophobic membrane-spanning domains (MSDs) and two nucleotide-binding
domains (NBDs) that are cytosolic [14, 15]. Structural studies of the ABC transporter
proteins revealed that the two cytosolic NBDs coordinate in a head-to-tail orientation to
form a “sandwich” dimer that generates two composite nucleotide binding sites.
Furthermore, the two membrane-spanning domains are intertwined to form the substratebinding site/s and the substrate translocation pathway and extend into the cytoplasm
making contacts with the NBDs. The binding and hydrolysis of ATP which is coupled to
substrate binding provides the energy required for the transport process [16]. The structure
of MRP1 and several “C” subfamily members contain an additional MSD at the aminoterminus of the protein, whose specific biological role is poorly understood.
MRP1 is an integral membrane protein that functions as an ATP-dependent drug efflux
pump. It localizes at the plasma membrane and can efflux a wide variety of endogenous
and exogenous substrates including toxic chemicals, drugs and their metabolites out of
cells. Overexpression of MRP1 can confer resistance against commonly used cytotoxic
anti-cancer agents like doxorubicin, vincristine, methotrexate and etoposide. MRP1overexpression has been associated with MDR of several types of cancers in clinics. In
addition to anti-cancer agents, MRP1 can reduce the efficacy of many commonly used
drugs including antibiotics, antivirals, antidepressants, anti-inflammatory and anti-HIV
drugs [8, 9, 10, 17, 18] Therefore, MRP1 is considered an important therapeutic target and
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may be used to improve the efficacy of various therapies including cancer chemotherapy.
On the other hand, MRP1 plays an important role in tissue defense and in regulation of
various biochemical processes such as redox homeostasis, steroid metabolism, lipid
metabolism, and the etiology of neurodegenerative, immunological, and cardiovascular
pathologies [19, 20]. It effluxes a remarkable variety of xenobiotics and organic anions
from endogenous sources, which are mostly conjugated to glutathione, glucuronide, or
sulfate. Physiological substrates of MRP1 include organic anions such as cysteinyl
leukotriene (LTC4), estradiol glucuronide (E217βG), glutathione (GSH), and cobalamin.
Automated fluorescence imaging-based high content screening platform is becoming very
popular in drug discovery and development research due to its capability to provide high
resolution in situ visual data that allows to simultaneously study multiple phenotypes. We
have recently demonstrated the development and validation of a high content imagingbased efflux assay using calcein-green as a substrate reporter of MRP1 transport activity
[9]. Using this assay in screening a unique library of 386 anti-cancer compounds, we
identified a total of 12 inhibitors of MRP1 that included 10 novel inhibitors not previously
reported to interact with MRP1. Doxorubicin, a cytotoxic anti-cancer drug, is a well-known
substrate of MRP1 and P-gp. However, it has not been successfully used in high-throughput
screening assays using flow cytometry or fluorescent microplate reader-based
methodologies likely due to its dimness and relatively poor affinity for the transporter
protein. Due to the polyspecificity and the promiscuous nature of MRP1 substrate binding,
we hypothesized that doxorubicin-based screening assay may identify novel inhibitors of
MRP1. In this study, we describe the development, optimization, and validation of a high
content imaging-based efflux assay using doxorubicin as a fluorescent reporter substrate.
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The value and effectiveness of this assay is demonstrated by screening the library of 386
anti-cancer drugs. The screening process identified a total of 28 inhibitors, which included
10 of 12 inhibitors discovered previously with calcein-green assay as well as 18 MRP1
inhibitors that were missed by the calcein-based screening. We verified the inhibitory
activity of the identified compounds using established methods and discovered 16
compounds that have not been previously known to inhibit MRP1. The ability of some
selected compounds to reverse the resistance of an MRP1-overexpressing MDR cancer cell
line is also demonstrated.

2.0 Materials and methods
2.1 Chemicals
Doxorubicin, adenosine monophosphate (AMP), adenosine triphosphate (ATP), estradiol
17-(β-D-Glucuronide) (E217βG), poly-D-lysine, thiazolyl blue tetrazolium bromide
(MTT) were procured from Sigma-Aldrich (St. Louis, MO). MK571 was acquired from
Cayman Chemical (Ann Arbor, MI) and [6,7-3H]E217βG (49.9 Ci mmol–1) from
PerkinElmer (Waltham, MA). Anti-cancer compound library consisting of 386 anti-cancer
small molecules under clinical trials for 12 different types of cancers was procured from
Selleck Chemicals (Houston, TX).
2.2 Cell lines and cell culture
H69 and H69AR cells were purchased from ATCC (Manassas, VA). HEK293T cells were
kindly provided by Dr. Adam Hoppe (South Dakota State University, Brookings, SD)
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while HEK293/pcDNA3.1, HEK293/BCRP and HEK293/P-gp (MDR1) were a kind gift
from Dr. Suresh V. Ambudkar (NIH, Bethesda, MD). HEK293 and H69 cell lines were
cultured in DMEM (GE Healthcare, Marlborough, MA) and RPMI 1640 (ATCC),
respectively, supplemented with 10% fetal bovine serum. Cells were grown in a humidified
incubator maintaining 5% CO2 at 37 °C. H69AR cells were exposed to 0.8 µM doxorubicin
once a month and cultured drug-free for a week before use.

2.3 MRP1 inhibition screening with automated image acquisition and analysis
Assay development and optimization were performed with H69 and H69AR cells with
doxorubicin as the fluorescent substrate and MK-571 as the positive inhibition control.
Cells were seeded at 6 × 104 cells per well in 100 µL culture medium in 96-well opticalbottom plates with polymer base (Thermo Fisher Scientific, Waltham, MA) coated with
poly-D-lysine (Sigma-Aldrich, St. Louis, MO) and incubated overnight. Culture medium
was removed prior to drug treatment and replaced with 80 µL of serum-free medium. For
pretreatment, 10 µL of test compounds (10 µM final concentration), DMSO (0.2% final
concentration) as negative control, or MK-571 (50 µM final concentration) as positive
control were added. Following the 30 min incubation, 10 µL of doxorubicin (10 µM final
concentration) was added and the cells were incubated for 2 h. At the end of the incubation
period, treatment was removed, cells were rinsed once and 100 µL of PBS containing
10mM HEPES and 4.5% glucose was added.
Images were obtained using an ImageXpress Micro XLS Widefield High-Content Analysis
System (Molecular Devices, Sunnyvale, CA) equipped with a 0.70 numerical aperture 60×
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objective. A total of 8 images (4 bright field and 4 fluorescent) were taken for each well.
Fluorescent images were acquired using a texas red filter with excitation and emission
wavelengths of 562/40 nm and 624/40 nm, respectively, with an exposure time of 100 ms.
As the intracellular accumulation of doxorubicin slowly dropped over time, a negative and
positive control were included in every two columns. Screening experiments were
performed three independent times. Fluorescent images were analyzed using the
MetaXpress software (version 5.10.41, Molecular Devices). Segmentation of fluorescent
objects on the texas red channel was done using a custom application module based on the
‘Find Blobs’ module. The custom module differentiates fluorescent accumulation from
background and artifacts by applying segmentation masks based on set parameters for
object size.

2.4 Flow cytometry-based doxorubicin accumulation assay
Flow cytometry was used to confirm the ability of drugs to inhibit MRP1 mediated efflux
of doxorubicin. H69AR cells were prepared in serum-free culture medium to a density of
7 × 105 cells/mL. For this assay, 1 mL of cells were incubated with test compounds (10
µM) at 37 °C for 1 hour after which 10 µM of doxorubicin was added for an additional 2
hours. Total DMSO concentration was maintained at 0.2% (v/v). Efflux activity of MRP1
was stopped by the addition of ice-cold PBS buffer. Cells were then collected, washed with
cold PBS and resuspended in ice-cold PBS containing 1% formaldehyde. Intracellular
fluorescence of doxorubicin was detected by BD Accuri C6 flow cytometer (BD
Biosciences, San Jose, CA) equipped with 488nm and > 670nm for excitation and emission
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respectively. Fluorescence intensity was collected as mean of 10,000 events. Treatments
were performed in duplicate and repeated in 3 independent experiments.

2.5 Doxorubicin accumulation assay using confocal microscopy
HEK293T cells were plated on poly-D-lysine-coated cover glass placed in a 6-well plate
at a density of 5 × 105 cells/well in 2 mL culture medium. Cells were transiently transfected
with an MRP1-GFP expression vector after 24 hours using jetPRIME Transfection Reagent
(Polyplus-transfection SA, Illkirch, France) according to the manufacturer’s protocol.
After 48 hours, cells were pre-treated with 10 µM test compound for 30 min, before
incubation with doxorubicin (10 µM) for 1 h. Cells were maintained in buffer (4.5 %
glucose, 10mM HEPES, PBS containing Ca2+ and Mg2+) as intracellular fluorescence was
visualized using an iMIC digital microscope (TILL Photonics GmbH, Gräfelfing,
Germany) equipped with a 1.35 numerical aperture 60x oil-immersion objective.
Excitation was done at 488 nm for GFP and doxorubicin, with emission bands of 475/42
and 605/64 nm, respectively. Images were processed using ImageJ (NIH, Bethesda, MD).

2.6 Membrane vesicle preparation
Membrane vesicles were prepared as described in [21] with modifications. Frozen cell
pellets of HEK293/pcDNA 3.1 and HEK293/MRP1 were thawed and suspended
containing 50 mM Tris.HCl, pH 7.4, 250 mM sucrose, 0.25 mM CaCl2, and 1x complete
protease inhibitors (Santa Cruz Biotechnology, Dallas, TX). Cell disruption was achieved
via nitrogen cavitation at 450 psi for 5 min. The resulting lysates were supplemented with
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1mM EDTA and centrifuged at 500 × g at 4 °C for 10 min. The supernatant was collected
twice by resuspending cell pellets and repeating centrifugation. Pooled supernatant was
layered over 35% (w/w) sucrose containing 10 mM Tris.HCl, pH7.4, and 1 mM EDTA and
centrifuged at 25,000 rpm at 4 °C for 1 h in a SW28 rotor (Beckman Coulter, Brea, CA).
The opaque membrane interface formed was collected and washed twice by
ultracentrifugation. The membrane pellet obtained was further resuspended in transport
buffer (50 mM Tris.HCl, pH 7.4, and 250 mM sucrose) and passed 20 times through a 27gauge needle for vesicle formation. Protein concentration was determined using Quick
Start Bradford Protein Assay (BioRad, Hercules, CA).

2.7 Membrane vesicular transport assay
A rapid filtration technique was used to measure the ATP-dependent transport of
[3H]E217βG into MRP1 enriched inside-out membrane vesicles [22]. The vesicles (2 µg
protein) were incubated with 400 nM/20 nCi [3H]E217βG for a minute at 37°C in a 30-µL
reaction mixture containing 4 mM AMP or ATP, 10 mM MgCl2, and test compound in
transport buffer (250 mM sucrose and 50 mM Tris-HCl, pH 7.4). Total DMSO
concentration was kept at 0.29%. Reaction was stopped by the addition of ice-cold buffer
and resulting mixture transferred to a 96-well MultiScreenHTS-FB plate (EMD Millipore,
Billerica, MA). Filter membranes were washed 4X with 200 µL ice-cold suspension buffer
under vacuum aspiration. Radioactivity retained on the membranes was measured using a
Tri-Carb 4810TR liquid scintillation counter (PerkinElmer, Waltham, MA). ATP-
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dependent uptake was calculated by subtracting the uptake measured in the presence of
AMP from the uptake in the presence of ATP. Treatments were performed in triplicates.
2.8 Drug sensitivity assay
The sensitivity of H69 and H69AR cells towards multiple chemotherapeutic drugs
(vincristine, doxorubicin, etoposide) and the ability of test compounds to reverse the
resistance of H69AR cells against these drugs were analyzed using the MTT colorimetric
assay. The sensitivity of

HEK293, HEK293/BCRP and HEK293/P-gp towards

mitoxantrone and vincristine respectively was also tested. H69 and HEK293 cells were
seeded in 96-well plates (CellBIND®, Corning) at 2.5 × 104 and 5 × 103 cells per well in
100 µL culture medium. After 24 h, cells were pretreated with 50 µL of test compounds in
culture medium and incubated for an hour. An additional 50 µL of cytotoxic drugs
(vincristine, doxorubicin, etoposide or mitoxantrone) at varying concentrations was then
added to the cells. Final DMSO concentration was maintained at 0.2%. Cells were further
incubated for 96 h (H69 cell lines) or 72 (HEK293 cell lines). At the end of the incubation
period, 100 µL of culture medium was carefully removed and cells were treated with MTT
(0.5 mg/mL) for 4 h. The formazan crystals were dissolved by the addition of 100 µL of
15% SDS containing 10 mM HCl and absorbance at 570 nm were recorded using a Hidex
Sense Beta Plus plate reader (Turku, Finland). Treatments were performed in triplicate.

2.9 High content screening data analysis
The MetaXpress software was used for analysis. The software derives the mean fluorescent
intensity of each well from averaging the fluorescent intensities of the segmentation mask
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of 4 captured images. The use of segmentation mask prevents the inclusion of background
fluorescence. The relative inhibition of each test compound on doxorubicin efflux was
determined for each well using the following equation:
,
where X represents the average fluorescent intensities and T represents the test compound.
Both positive and negative controls were placed in every two columns and used for the
determination of the percent inhibition for compounds within the same columns. The Z’factor, a parameter commonly used to infer the versatility and variation of an assay [23]
was determined with the following equation:
,
where σ and μ represent the standard deviations and means, respectively.

2.10 Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics (IBM, Armonk, NY). The
differences between mean values were analyzed using linear mixed model analysis. Dunnet
correction was applied for multiple comparisons. For all analyses, differences were
considered significant at P value lower than 0.05.
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3.0 Results
3.1 Assay development and optimization
Calcein-AM, a well-known substrate for MRP1 and P-gp, is commonly used to study the
activity of these transporters in cell-based assays. We recently reported the development
of an imaging-based high-throughput efflux assay for MRP1 using calcein-AM in high
content screening system which offers a much more robust and efficient system compared
to a fluorescent microplate reader or flow cytometer [9]. Doxorubicin, a fluorescent
compound and a well-known substrate of MRP1 and P-gp, is a very commonly used
cytotoxic chemotherapeutic agent for various types of cancer. However, due to its
relatively low affinity for MRP1 and P-gp the efflux assay produces a very narrow dynamic
range between positive and negative controls. In addition, high non-specific background
fluorescence gives many false hits and has not worked well for MRP1 inhibitor screening
using fluorescence intensity-based microplate reader method. Consequently, doxorubicin
has not been successfully used as a substrate reporter in high-throughput efflux assays.
Here, High-Content Screening System which contains advance image analysis and
quantitation tools was used to develop an imaging-based high-throughput efflux assay for
MRP1 using doxorubicin as a fluorescent substrate reporter. We used parental H69 cell
line and its MRP1-overexpressing derivative H69AR cell line for the development of this
assay. The basic idea is that H69 cells are expected to show higher levels of fluorescence
due to very low expression levels of endogenous MRP1 and other transporters capable of
effluxing doxorubicin. In contrast, H69AR cells over-expressing MRP1 will show much
lower fluorescence accumulation under similar experimental conditions due to active
doxorubicin efflux.
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Fluorescent intensities of images were quantified using the ‘Find Blobs’ option in the
custom module of the MetaXpress software. Cells were identified using object
segmentation in the texas red channel. To develop and optimize the assay conditions, both
time and concentration dependent accumulation of doxorubicin in H69 and H69AR cells
were studied. As shown in Fig. 2.1A, increased concentrations of doxorubicin yielded an
increase in intracellular fluorescence in both cell lines. However, intracellular
accumulation of doxorubicin was much higher in the parental H69 cells as compared with
MRP1-overexpressing H69AR cells for all tested concentrations. To determine if the
difference observed between the two cell lines is specifically due to MRP1 transport
activity, effect of MRP1 inhibitor, MK571, was observed at different doxorubicin
incubation times. As shown in Fig. 1B, MRP1 inhibition by MK571 did not affect the
doxorubicin accumulation in H69 cells irrespective of the doxorubicin incubation time. In
contrast, MRP1-overexpressing H69AR cells showed much higher doxorubicin
accumulation with MK571 treatment compared with untreated H69AR cells at all
doxorubicin incubation time points (Fig. 2.1C). These data provide the basis and feasibility
of using H69AR cells to develop a high-throughput screening assay to identify inhibitors
of MRP1 using doxorubicin as a fluorescent substrate reporter.
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Figure 2.1 Concentration- and time-dependent accumulation of doxorubicin in H69 and
H69AR cells
A. H69 and H69AR cells were treated with doxorubicin at various concentrations (1–30
µM) for 1 h. Representative images of doxorubicin treatment at 1, 3, and 10 µM are shown.
The average fluorescence intensities derived from the fluorescent images were graphed and
shown on the right. B. H69 cells were treated with 10 µM doxorubicin in the absence and
presence of 50 µM MK571 for 15–180 min. Representative images of doxorubicin
treatment at 30, 60, and 90 min are shown. C. H69AR cells were treated with 10 µM
doxorubicin in the absence and presence of 50 µM MK571 for 15–180 min. Representative
images of doxorubicin treatment at 30, 60, and 90 min are shown. Data are representative
of two experiments and shown as mean ± SD (n = 3).

3.2 Screening of anti-cancer compound library for MRP1 inhibitors
After the development and optimization of high-content imaging-based MRP1 efflux assay
using doxorubicin, we sought to identify novel MRP1 inhibitors within a library of 386
anti-cancer small molecules under clinical trials for 12 different types of cancers. The anticancer library was screened using MRP1-overexpressing H69AR cells and doxorubicin as
a fluorescent substrate reporter. Treatment with 50 µM MK571 (a commonly used MRP1
inhibitor) was considered as 100% MRP1 inhibition for calculating percent inhibition for
the test compounds. Three independent screening experiments were done using the 96-well
format. The relative MRP1-inhibitory activities of the test compounds from three
independent experiments are represented as a 3D scatter plot (Fig. 2.2). As indicated in
Fig. 2.2 (bottom), the assay had good reproducibility with a correlation range of 0.73-0.85
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between any two given experiments. The quality and performance of the assay was also
assessed by deriving the Z’-factor from the experiments. The average Z’-factor across all
plates was 0.58, indicating a good assay performance. A positive hit was defined as a
compound with ≥ 40% mean percent inhibition. Using this threshold value, we identified
a total of 33 hit compounds. Five of the hits were autofluorescent compounds and were
discarded. The remaining 28 hit compounds are displayed as red dots in the 3D scatter plot
(Fig. 2). Identified MRP1 hits, together with their therapeutic targets and percent inhibition
are shown in Table 1. Ten of the 28 hits were recently identified by our group by screening
the anti-cancer library using calcein as a fluorescent substrate and are listed in Table 1 as
well. Among the remaining 18 hit compounds, celecoxib and LY294002 have been
reported as MRP1 inhibitors [24, 25] while 16 anti-cancer hit compounds have not been
previously reported to inhibit MRP1 transport activity. The structure of the 18 hit
compounds is presented in Fig. 2.3.
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Correlation coefficient

Figure 2.2 Performance of the imaging-based MRP1-mediated doxorubicin accumulation
screening assay
Screening of the anti-cancer compound library was performed in three independent
experiments at compound concentration of 10 µM. The relative inhibitory activities of each
compound were calculated and displayed as a 3D plot. Red dots represent compounds with
mean percent inhibition of ≥50%. The table below the plot shows correlation coefficients
between any two experiments. 3D scatter plot was generated using SigmaPlot 12.0 and
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correlation coefficients were calculated using MS Excel. Correlation and graph exclude 5
compounds identified as autoflourescent.

55

Table 2.1 Chemotherapeutic targets, % inhibition for calcein/doxorubicin
accumulation inhibition for identified MRP1 inhibitors
Compound

Chemotherapeutic
targets

MK-571

%
Doxorubicin
Inhibition

%
Calcein
Inhibition

100.0 ± 0

100.0 ± 0

Tipifarnib

Transferase

86.3 ± 9.3

199.1 ± 56.8

AZD1208

Pim

71.2 ± 13.8

145.7 ± 25.3

Rapamycin

Autophagy

66.1 ± 10.0

142.5 ± 12.2

Deforolimus

mTOR

74.6 ± 10.9

111.9 ± 19.4

HS-173

PI3K

86.7 ± 7.7

94.0 ± 21.8

YM201636

PI3K

54.3 ± 5.9

81.9 ± 4.9

ESI-09

74.6 ± 11.8

Everolimus

mTOR

69.2 ± 4.6

72.6 ± 7.8

TAK-733

MEK

59.4 ± 8.9

67.4 ± 12.7

CX-6258

Pim

Cyclosporin A

57.1 ± 16.4
61.3 ± 11.6

50.2 ± 2.7
43.3 ± 4.2

Temsirolimus

mTOR

45.0 ± 4.0

GSK2126458

mTOR

94.0 ± 13.5

Flavopiridol

CDK

68.4 ± 7.1

Mifepristone

67.5 ± 7.1

NVP-BSK805

JAK

65.8 ± 0.8

Saracatinib

Src

65.7 ± 3.4

Alisertib

Aurora A kinase

64.1 ± 10.3

OSI-420

EGFR

57.8 ± 2.7

LY294002

PI3K

56.6 ± 5.3

Rosiglitazone

56.1 ± 3.6

Alvespimycin

HSP90

55.9 ± 7.4

MK-2206

AKT

54.1 ± 16.0

Celecoxib

COX-2

53.4 ± 6.7

Amuvatinib

C-Kit

53.3 ± 6.5

LY2228820

P38 MAPK

53.3 ± 4.1

GSK461364

PIK1

52.7 ± 1.3

GW4064

FXR

52.3 ± 1.8

Afatinib

EGFR

50.9 ± 7.7

Doramapimod

MAPK

50.8 ± 2.0
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Figure 2.3 Chemical Structures of the selected 18 hit compounds.
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3.3 Validation of identified MRP1 inhibitors
To verify the inhibitory activities of the hit compounds obtained from the initial highcontent screening and to identify any false hits, we performed doxorubicin accumulation
assay using two different traditional and well-established methods. First, we used confocal
microscopy to visualize the inhibitory effects of the hit compounds on MRP1-mediated
doxorubicin efflux. For this assay, HEK293T cells were transiently transfected with a
vector encoding recombinant MRP1-GFP protein. The beauty of this experiment is that
transient transfection allows mixed population of cells with and without MRP1-GFP and
creates negative control within the system to easily visualize MRP1-dependent doxorubicin
efflux side by side in the same image. As shown in Fig. 2.4A, no drug treatment control
cells showed high doxorubicin accumulation in the nuclei of non-transfected cells, while
doxorubicin fluorescence was very low or undetectable in cells expressing MRP1-GFP.
MRP1-mediated efflux of doxorubicin was blocked by MK-571 (50 µM), which was used
as the positive control. All the test compound (10 µM) treatments increased doxorubicin
accumulation in MRP1-GFP expressing cells to a certain extent reflecting inhibition of
doxorubicin efflux by MRP1. Treatment with NVP-BSK805 showed the weakest response.
Next, we also performed more quantitative doxorubicin accumulation assay using flow
cytometry method. In this assay, MRP1-overexpressing H69AR stable cells were pretreated with the test compounds for 1 hour before treatment with doxorubicin for another
2 hours. As shown in Figure 4B, MK-571 at 50 µM enhanced doxorubicin accumulation
in H69AR cells by 2-fold compared to no treatment control. All the tested hit compounds
(10 µM) exhibited increased doxorubicin accumulation in H69AR cells to varying levels
(~1.5 to 2.7-fold). Based on both confocal and flow cytometry assays, hit compounds
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GSK2126458, doramapimod, MK2206, mifepristone and celecoxib showed strong
inhibition of doxorubicin efflux by MRP1 while the remaining compounds showed
moderate to weak inhibition.
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Figure 2.4 Validation of MRP1-inhibitory activity of identified hit compounds
A. HEK293T cells transiently transfected with MRP1-GFP (green) were pre-treated with
10 µM test compounds for 30 min, before treatment with doxorubicin (red) at 37 °C for 1
h. Images were acquired using confocal microscopy. GFP and doxorubicin were excited at
488 nm, and detected at 475/42 and 605/64 nm, respectively. B. H69AR cells were pretreated with 50 µM MK571 or 10 µM test compounds for 1 h before treatment with 10 µM
doxorubicin at 37 °C for 2 h. Fluorescence intensities of intracellular doxorubicin were
detected using flow cytometry, with excitation and emission wavelengths of 488 and
610/20 nm, respectively. Data are combined from two experiments and presented as mean
± SEM. *, p value lower than 0.05 compared with control.

3.4 Membrane Transport assay for MRP1 inhibitors
Since MRP1 plays a very important physiological role in detoxification and tissue defense.
We were interested in evaluating the effects of the hit compounds on MRP1-mediated
transport of endogenous organic anions. For this purpose, we employed membrane-based
vesicular uptake assay for E217βG, a glucuronide conjugate and a prototypical
physiological substrate of MRP1. HEK293/pcDNA 3.1 and HEK293/MRP1 cells were
used to prepare membrane vesicles. MRP1 transport activity was measured using
[3H]E217βG as substrate and hit compound treatments were done at 10 µM. As shown in
Fig. 2.5, ATP-dependent uptake of [3H]E217βG into HEK293/pcDNA3.1 (vector control)
membrane vesicles was less than 1% of uptake by HEK293/MRP1 membrane vesicles.
Uptake of [3H]E217βG into HEK293/MRP1 membrane vesicles was reduced by ~95% with
10 µM MK571. Among the hit compounds, alisertib, GSK461364 and GW4064 exhibited
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strong MRP1 inhibition and reduced the uptake of [3H]E217βG by 66%, 67% and 70%
respectively. In contrast, afatinib, celecoxib, doramapimod, flavopiridol, LY294002, MK2206, OSI-420, rosiglitazone and saracatinib showed no inhibition or modest inhibition of
[3H]E217βG uptake into HEK293/MRP1 membrane vesicles.
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Figure 2.5 Effects of test compounds on [3H]E217βG uptake into MRP1 expressing
membrane vesicles.
Membrane vesicles were prepared from stable HEK293/pcDNA3.1 and HEK293/MRP1
cells. Membrane vesicles (2 µg protein) were incubated with 10 µM test compounds.
Reactions were performed using 400 nM/20 nCi [3H] E217βG at 37 °C for 1 min.
Radioactivity retained on collected membrane vesicles was quantified using liquid
scintillation counting. Data are combined from two experiments and presented as mean ±
SEM, * p value lower than 0.05 compared with control.
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3.5 Resistance reversal by selected MRP1 inhibitors
Development of MDR is the biggest hurdle in the success of chemotherapy. We were
interested to determine if the identified anti-cancer hit compounds can reverse drug
resistance in a MRP1-overexpressing MDR cell line. MDR reversal ability of a drug may
be valuable in combinatorial therapies of malignancies where MRP1 is overexpressed. In
addition, drugs which show substrate selectivity and can inhibit the efflux of cancer drugs
without significantly interfering with the efflux of physiological organic anions by MRP1
may have a better chance of success in chemotherapy. We selected 6 compounds (afatinib,
celecoxib, doramapimod, mifepristone, MK-2206 and rosiglitazone) from the total 18 hit
compounds to conduct resistance reversal experiments based on the available data. The
abilities of the selected compounds were evaluated to reverse resistance of MRP1overexpressing H69AR lung cancer cells against vincristine, doxorubicin and etoposide.
These cytotoxic anti-cancer agents are very commonly used in chemotherapy and are wellestablished substrates of MRP1. First, concentration response was conducted for selected
drug hits to evaluate the cytotoxicity profile of these compounds in H69AR (data not
shown). Selected hit compounds at non-cytotoxic concentrations were then administered
in combination with increasing concentrations of vincristine, doxorubicin or etoposide to
determine the resistance level of H69AR cells. As shown in Fig. 6, MRP1-overexpressing
H69AR cells (solid red) showed MDR and as expected exhibited much lower sensitivity
towards each of the three cytotoxic cancer drugs than H69 cells (dotted red). IC50 values
and fold resistance of the parental H69 and the MRP1-overexpressing derivative H69AR
cells treated with vincristine, doxorubicin or etoposide with or without the selected
compounds are presented in Table 2.2.
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In case of vincristine, H69AR cells were 35-fold more resistant than the parental H69 cells
and MRP1 inhibitor MK571 (10 µM) reduced the fold resistance of H69AR cells to 14fold. Among the selected 6 hit compounds, mifepristone and doramapimod were most
effective in sensitizing H69AR cells against vincristine and reduced the fold resistance to
3 and 6-fold respectively. The remaining hit compounds showed comparable reversal as
standard MRP1 inhibitor MK571. H69AR cells were 23-fold more resistant towards
doxorubicin compared with H69 cells. Mifepristone and rosiglitazone proved most
effective in sensitizing H69AR cells against doxorubicin and reduced the fold resistance to
2.6 and 3.1-fold respectively. Afatinib, alisertib, celecoxib and doramapimod showed
similar resistance reversal as MK571. In the absence of any inhibitor, H69AR cells also
exhibited 5.6-fold more resistance towards etoposide compared with H69 cells.
Doramapimod, celecoxib and alisertib were able to completely reverse resistance of
H69AR cells against etoposide. In contrast, presence of afatinib failed to show any
reduction in the resistance level against etoposide. Hit compounds mifepristone, MK-2206
and rosiglitazone showed only moderate levels of reduction in resistance of H69AR cells
against etoposide.
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Figure 2.6 Reversal of drug resistance towards vincristine, doxorubicin and etoposide in
H69AR cells by selected MRP1 inhibitors.
A. H69 and H69AR cells were treated with vincristine at increasing concentrations in the
absence and/or presence of selected MRP1 inhibitors. B. H69 and H69AR cells were
treated with doxorubicin at increasing concentrations in the absence and/or presence of
selected MRP1bitors C. H69 and H69AR cells were treated with etoposide at increasing
concentrations in the absence and/or presence of selected MRP1 inhibitors. A, B and C.
MK571, doramapimod, mifepristone, and rosiglitazone were at 10 µM, MK-2206 and
celecoxib were at 2 µM, afatinib was at 1 µM. Cell viability was evaluated with MTT after
72 h. Data are representative of three experiments and presented as mean ± SD (n = 3).
Table 2.2 The effects of selected MRP1 inhibitors on the IC50 values of vincristine,
doxorubicin and etoposide in H69 and H69AR cells
Cell line/Treatment

Vincristine
IC50 a (nM)

Fold

Doxorubicin
IC50 a (µM)

resistance b

Fold

Etoposide
IC50 a (µM)

Fold resistance b

resistance b

H69

0.67 ± 0.08

1.00

0.14 ± 0.05

1.00

4.43 ± 1.97

1.00

H69AR

23.35 ± 0.34

34.69

3.31 ± 0.32

22.93

24.68 ± 2.23

5.57

H69AR + MK571 10 µM

9.33 ± 1.43

13.86

1.05 ± 0.04

7.25

7.97 ± 1.10

1.80

H69AR + Afatinib 1 µM

14.68 ± 1.57

21.80

1.16 ± 0.21

8.05

28.34 ± 1.03

6.40

H69AR + Celecoxib 2 µM

10.54 ± 0.19

15.66

1.19 ± 0.15

8.28

4.78 ± 0.35

1.08

H69AR + Doramapimod 10

4.08 ± 0.06

6.06

1.21 ± 0.25

8.39

4.18 ± 0.52

0.94

2.13 ± 0.40

3.16

0.38 ± 0.10

2.65

11.58 ± 1.99

2.62

H69AR + MK-2206 2 µM

15.40 ± 2.5

22.87

2.09 ± 0.05

14.50

14.54 ± 1.89

3.28

H69AR + Rosiglitazone 10

14.85 ± 1.13

22.20

0.44 ± 0.05

3.07

13.14 ± 0.03

2.97

µM
H69AR + Mifepristone 10
µM

µM
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a

Mean ± SEM of n ≥ 3 independent experiments.

b

Fold resistance is the ratio between IC50 value of each treatment and IC50 value of

vincristine, doxorubicin and etoposide alone in H69 cells.

3.6 Effects of selected hit compounds on drug sensitivity of HEK293/BCRP and
HEK293/P-gp cells
Among ABC drug transporters, P-gp, MRP1 and BCRP are most frequently implicated in
MDR. Therefore, we were interested in investigating the potential of selected MRP1
inhibitors to reverse drug resistance of P-gp and BCRP-overexpressing cell lines.
HEK293/BCRP and HEK293/P-gp cells were treated with increasing concentrations of
mitoxantrone and vincristine, respectively, in the presence and absence of selected hit
compounds. Ko143 and verapamil were used as known inhibitors of BCRP and P-gp,
respectively. As shown in Fig. 7, BCRP and P-gp-overexpressing cells (solid red) exhibited
much lower sensitivity towards mitoxantrone and vincristine, respectively, than the vector
control cell line HEK293/pcDNA3.1 (dotted red). Treatment of HEK293/BCRP and
HEK293/P-gp cells with Ko143 and verapamil, respectively, reversed the resistance of the
cells. IC50 values and fold resistance are presented in Table 3. Doramapimod and
mifepristone were able to completely reverse the resistance of HEK293/BCRP cells against
mitoxantrone while the remaining selected hits showed only modest to moderate reversal.
In case of HEK293/P-gp cells, mifepristone treatment completely reversed the resistance
against vincristine while doramapimod exhibited modest resistance reversal. In contrast,
treatment with afatinib or celecoxib led to increased resistance of HEK293/P-gp cells
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against vincristine. Alisertib, MK-2206 and rosiglitazone did not significantly reduce the
resistance levels of HEK293/P-gp cells.

Figure 2.7 Effects of selected MRP1 inhibitors on drug sensitivity of HEK293/BCRP and
HEK293/P-gp cells. HEK293/BCRP
(A) and HEK293/P-gp (B) were treated with increasing concentrations of mitoxantrone
and vincristine, respectively in the absence and /or presence of selected MRP1 inhibitors.
Afatinib was at 1µM, celecoxib and MK-2206 were at 2 µM while doramapimod,
mifepristone and rosiglitazone were at 10 µM. Ko143 (1 µM) and verapamil (25 µM) were
used as positive controls in HEK293/BCRP and HEK293/P-gp cells, respectively.
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HEK293/pcDNA cells were included as negative control for drug resistance. Cell viability
was evaluated with MTT after 72 h. Data are representative of three experiments and
presented as mean ± SD (n = 3).
Table 2.3 Effect of selected MRP1 inhibitors on IC50 of mitoxantrone and vincristine
and in HEK293/BCRP and, HEK293/P-gp respectively
Cell line/Treatment

a

b

Mitoxantrone

Vincristine

IC50 a (nM)

Fold
resistance b

IC50a (µM)

Fold
resistance b

HEK293/pcDNA3.1

4.57 ± 1.48

1

HEK293/BCRP (control)

28.36 ± 4.1

6.21

HEK293/BCRP + Ko143 1µM

1.33 ± 0.14

0.29

HEK293/BCRP + Afatinib 1µM

17.37 ± 1.58

3.80

HEK293/BCRP + Celecoxib 2 µM

19.91 ± 3.68

4.36

HEK293/BCRP + Doramapimod 10 µM

2.52 ± 0.22

0.55

HEK293/BCRP + Mifepristone 10 µM

4.40 ± 0.33

0.96

HEK293/BCRP + MK-2206 2 µM

22.5 ± 1.85

4.93

HEK293/BCRP + Rosiglitazone 10 µM

20.04 ± 4.68

4.39

HEK293/pcDNA3.1

0.0037 ± 0.0013

1

HEK293/P-gp (control)

1.40 ± 0.17

376.86

HEK293/ P-gp + Verapamil 25 µM

0.0030 ± 0.0012

0.80

HEK293/ P-gp + Afatinib 1 µM

2.92 ± 0.09

788.73

HEK293/ P-gp + Celecoxib 2 µM

3.83 ± 0.46

1034.51

HEK293/ P-gp + Doramapimod 10 µM

0.12 ± 0.07

31.23

HEK293/ P-gp + Mifepristone 10 µM

0.0032 ± 0.0002

0.88

HEK293/ P-gp + MK-2206 2 µM

0.81 ± 0.46

218.64

HEK293/ P-gp + Rosiglitazone 10 µM

0.58 ± 0.07

157.86

Mean ± SEM of n ≥ 3 independent experiments
Fold resistance is the ratio between IC50 value of each treatment and IC50 value of

mitoxantrone or vincristine alone in the parental cell line HEK293/pcDNA3.1.
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4.0 Discussion
MDR is a major problem in the treatment of malignancies as it increases the effective dose
of anticancer agents to more lethal levels. The capacity of MRP1 to efflux drugs prevents
the effective treatment of cancers when overexpressed. MRP1 although localizes primarily
at the plasma membrane of the cells, has also been found in the membranes of sub-cellular
organelles such as mitochondria, endoplasmic reticulum and endocytic vesicles [26]. The
localization of MRP1 in sub-cellular organelles has been hypothesized to serve as a
sequestering mechanism to prevent drugs from reaching their respective intracellular
targets [3, 27]. MRP1 is known to be overexpressed in cancers such as neuroblastoma [28],
acute lymphoblastic leukemia [29], breast [30], tongue [31], brain [32], small-cell lung
carcinoma [33] and prostate [34]. It has also been linked with survival of patients with
ovarian [35], neuroblastoma [36] and acute leukemia [37]. MRP1-overexpression has been
implicated with MDR in lung, breast, prostate cancers and different types of leukemia.
Inhibition of MRP1-mediated transport by small molecules to resensitize drug resistant
cells provides the possibility of overcoming MDR in malignancies where MRP1 is
overexpressed and linked to patient survival.
Chemotherapy is the most common type of treatment for various types of cancers.
Conventional cytotoxic anticancer drugs such as vincristine, doxorubicin, cisplatin,
paclitaxel, and methotrexate are still commonly used in cancer chemotherapy. Because
these agents target essential and fundamental cellular processes, they are very cytotoxic
and not cancer specific. Major problems limiting the success of chemotherapy are MDR,
tumor cell heterogeneity and toxicity. To address MDR and tumor heterogeneity,
combination cancer therapy is frequently used, where drugs from different families
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targeting different cellular mechanisms are combined to achieve better outcomes. To
address the toxicity issue associated with chemotherapy, the focus in cancer therapeutics
is to identify drugs that show high selectivity towards cancer cells and target specific cell
signaling pathways. Many new compounds have been discovered that target specific
enzymes, kinases, and receptors, and are being tested in clinical trials for better efficacy
and reduced toxicity. Given the remarkable ability of MRP1 to significantly alter the
bioavailability of a broad spectrum of drugs and the fact that MRP1-overexpression has
been implicated in MDR of different types of cancer, it is very important to profile any
new anticancer drug candidates for their interaction with this transporter. For successful
cancer treatment, especially in cancers where MRP1-overexpression is associated with
poor clinical outcome, it will be desirable to either inhibit MRP1 activity or use drugs that
are not substrates of MRP1. In this study we investigated the interaction of MRP1 with a
unique library of anti-cancer compounds which are being clinically tested as targeted
cancer drugs. We are especially interested to identify inhibitors of MRP1 from this library
because such compounds can act as dual-edge sword. In addition to working as a targeted
cancer drug, it can also reverse MRP1-mediated drug resistance or can be used to improve
the efficacy and reduce the toxicity of MRP1 substrate drugs.
In the present study, we have successfully developed and validated a high content imagingbased efflux assay for MRP1 transport activity using doxorubicin as a fluorescent reporter
substrate. To the best of our knowledge, doxorubicin has never been successfully used as
a substrate in a high content screening or any other high-throughput screening assay to
identify inhibitors of MRP1 activity. Screening a unique library of 386 anti-cancer
compounds currently under clinical trials targeting 12 types of cancers, we identified a total

72

of 28 MRP1 inhibitors. The assay exhibited high correlation (0.73−0.85) among the three
independent screening experiments. The high quality and performance of this screening
assay was demonstrated by Z’-factor of 0.58 across all plates. The high-through screening
assay developed in this study has several advantages over assays that measure fluorescence
intensity using microplate reader or flow cytometry. This high-content screening method
uses automated imaging and offers very advance and sophisticated image analysis tools to
remove the non-specific and background fluorescence leading to a very robust and precise
assay with high dynamic range between the positive and negative controls. In addition, this
live cell-based assay allows simultaneous detection of cell permeable, non-toxic and potent
inhibitors. There is convincing biochemical and structural data to suggest that MRP1 has
multiple distinct substrate binding sites. However, only calcein-AM as a substrate has been
used in cell-based assays for MRP1 inhibition screening. The doxorubicin-based new assay
developed was able to identify 10 of 12 hits previously identified using calcein-based
screening and in addition discovered many new drugs as inhibitors of MRP1. These
findings suggest that doxorubicin binding site overlaps with calcein binding site and may
have an additional binding site. Furthermore, the new assay signifies the importance of
MRP1 for drug discovery and development.
Among the 28 hit compounds identified as MRP1 inhibitors in the doxorubicin-based
screening of anticancer compounds, 10 compounds (tipifarnib, AZD1208, rapamycin,
deforolimus, HS-173, YM201636, everolimus, TAK-733, cyclosporin A, and
temsirolimus) were recently identified by our group using calcein-based screening assay.
Therefore, we focused on the characterization of the remaining 18 MRP1 inhibitors. Two
of the novel inhibitors identified in this study, namely alisertib and amuvatinib, are being
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actively investigated for their anticancer efficacy and have never been reported to interact
with any ABC drug transporter. Alisertib, a second-generation aurora kinase A and B
inhibitor with a higher affinity for aurora kinase A is identified for the first time to interact
with MRP1. Alisertib showed strong inhibition of MRP1-mediated transport of
doxorubicin and E217βG (Fig. 3 and 4). P-gp and BCRP expression have been reported to
decrease the anti-cancer activity of pan-aurora kinase inhibitor tozasertib but not of the
aurora kinase inhibitor alisertib indicating that alisertib is not a substrate of these ABC
transporters [38, 39]. Two compounds, celecoxib and LY294002, have been previously
shown to inhibit MRP1 efflux function [24, 25] while anti-cancer drugs mifepristone and
rosiglitazone although have not been reported to be a substrate or inhibitor of MRP1
directly but have been shown to reverse resistance of cells overexpressing P-gp and MRP1
[40, 41].
Eleven of the 18 hit drugs have been reported previously to be a substrate or inhibitor of
P-gp or BCRP but not have been reported to interact with MRP1. GW4064 has been
reported to induce the MRP2 mRNA levels [42] while MK2206 was reported to decrease
P-gp expression [43] but neither of these drugs has been reported as substrate or inhibitor
of P-gp, BCRP or MRP1. In addition to cell-based assays that measured doxorubicin efflux
inhibition, we also employed membrane-based vesicular uptake assay to evaluate the
effects of hit compounds on MRP1-mediated transport of endogenous organic anion,
E217βG, a prototypical physiological substrate of MRP1. Ten of the 18 compounds
(LY294002, OSI-420, rosiglitazone, MK-2206, flavopiridol, doramapimod, afatinib,
celecoxib, alvespimycin and amuvatinib) showed no or weak inhibition of MRP1-mediated
E217βG transport. Substrate selective inhibition of MRP1 may be very critical in the
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potential application of these anti-cancer agents in reversing MDR. An anti-cancer agent
that blocks the efflux of therapeutic drug without interfering with the efflux of important
physiological substrates may exhibit less toxic side effects.
Six of the hit compounds were evaluated to reverse resistance of MRP1-overexpressing
H69AR lung cancer cells against vincristine, doxorubicin and etoposide. Mifepristone,
doramapimod and celecoxib were most effective in reversal of MRP1-mediated drug
resistance. Mifepristone is a progesterone and glucocorticoid hormone antagonist and has
been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.
Mifepristone has been reported to reverse drug resistance in cells overexpressing P-gp as
well as in SGC790/VCR cell line overexpressing both P-gp and MRP1. In this study,
mifepristone was able to sensitize MRP1-overexpressing H69AR cells against vincristine
(reduced IC50 from 23.35 to 2.13 nM), doxorubicin (reduced IC50 from 3.3 to 0.38 nM), and
etoposide (reduced IC50 from 24.68 to 11.58 µM). We report that mifepristone is a MRP1,
P-gp and BCRP pan inhibitor since it was able to completely reverse resistance of P-gp and
BCRP-overexpressing cells against vincristine and mitoxantrone, respectively. As of June
16th, 2019, there are currently 146 clinical trials registered (clinicaltrials.gov) and many of
them are focused on evaluating the anti-cancer potential of mifepristone for various types
of cancers. Doramapimod is a p38 MAPK inhibitor and has been reported to enhance
cytotoxicity of anticancer drugs in P-gp overexpressing cell lines [44]. We are the first to
report its interaction with MRP1. In this study, doramapimod was able to sensitize MRP1overexpressing H69AR cells against vincristine (reduced IC50 from 23.35 to 4.08 nM),
doxorubicin (reduced IC50 from 3.3 to 1.21 nM), and etoposide (reduced IC50 from 24.68
to 4.18 µM). Here we report that doramapimod is a MRP1, BCRP and P-gp pan inhibitor
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since it was able to completely reverse resistance of BCRP-overexpressing cells against
mitoxantrone and exhibited strong resistance reversal of P-gp overexpressing cells against
vincristine. Celecoxib is a selective cyclooxygenase inhibitor. In this study, celecoxib was
able to completely reverse the resistance of MRP1-overexpressing H69AR cells against
etoposide whereas only modest drug reversal was observed against vincristine and
doxorubicin reflecting substrate selective inhibition. In contrast, we observed that
celecoxib enhanced the cytotoxicity of vincristine in HEK-P-gp overexpressing cells. In
addition, we report that celecoxib was ineffective in reversing resistance of HEK-BCRP
overexpressing cells against mitoxantrone. Interestingly, a gene array analysis
investigating the expression of all 48 human ABC transporters found ABCC1 and ABCC6
to be highly expressed in the MCF7VP breast cancer cell line (etoposide-resistant cell line)
compared to the MCF7 (parental sensitive cell line) whereas the expression of other
transporters was not appreciably increased [45]. This report is consistent with our findings
and highlights the role of MRP1 in resistance against etoposide.
In summary, we demonstrated the effectiveness and value of a novel doxorubicin-based
high content imaging-based assay to study compound interaction with MRP1. This study
identified 16 anti-cancer agents as MRP1 inhibitors which have not been previously
reported as a substrate or inhibitor of MRP1. The anti-cancer drugs which did not exhibit
interaction with MRP1 may have a lower risk of being interfered by MRP1-mediated
MDR.
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CRO-9 screening of unique anticancer library identifies novel inhibitors of human
MRP1 (ABCC1).

Abstract
Multidrug resistance protein 1 (MRP1/ABCC1) transports a variety of drugs, toxic
molecules and important physiological substrates across the plasma membrane and
physiological barriers. MRP1 plays an active role in protecting cells by effluxing a vast
array of drugs to sub-lethal levels. Additionally, its overexpression has been implicated in
multidrug resistance in various cancers. We recently reported development of a high
content efflux assay using doxorubicin as fluorescent reporter which identified MRP1
inhibitors missed by calcein-AM in a similar assay. Here, we describe the development of
a new high content imaging-based efflux assay using CRO-9 as a fluorescent reporter.
Taking advantage of multiple binding sites of MRP1, we screened the same anti-cancer
library of 386 compounds using CRO-9. The new assay identified a total of 50 MRP1
inhibitors including 19 inhibitors that have not been previously reported as inhibitors of
MRP1. The inhibitory activity of compounds was confirmed using flow cytometry
confocal microscopy, and membrane vesicle-based transport assays. Six drugs
(GSK650394, KU-0063794, LY2603618, MK0752, NU7441 and ZSTK474) were
evaluated for their ability to reverse resistance of MRP1-overexpressing H69AR lung
cancer cells against vincristine, and SN38. LY2603618 and ZSTK474 were the most
effective in reversing resistance of H69AR cells against vincristine and SN38. NU7441
was more effective in reversing resistance against SN38 as compared to resistance of
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H69AR to vincristine. Our findings indicate the importance of MRP1 in drug discovery
and demonstrate the advantage of CRO-9 as a fluorescent reporter in a high content
screening assay. Anti-cancer agents that exhibit MRP1 inhibition and ability to reverse
resistance may be used in combination therapy to improve the efficacy and reduce the
toxicity of other cancer chemotherapies.

Keywords: MRP1; ABCC1; ABC transporter; multidrug resistance; MRP1 inhibitors; high
content screening; anti-cancer agent; drug-transporter interactions; CRO-9; drug profiling

Chemical compounds studied in this article:
1) AUY922 (PubChem CID: 135539077); 2) BIBR 1532 (PubChem CID: 9927531); 3)
Bosutinib (PubChem CID: 5328940); 4) CT99021(9956119); 5) CW069 (PubChem CID:
73427517); 6) Evista (PubChem CID: 59400); 7) Gefitinib (PubChem CID: 123631); 8)
GSK1120212 (PubChem CID: 11707110); 9) GSK650394 (PubChem CID: 5022668); 10)
Ibrutinib (PubChem CID: 24821094); 11) Ku-0063794 (PubChem CID: 16736978); 12)
Ku-55933 (PubChem CID:5278369); 13) Ly2603618 (PubChem CID: 11955855); 14)
Mk-0752 (PubChem CID: 9803433); 15) Nu7441(PubChem CID:11327430); 16) Nutlin
3(PubChem CID: 11433190); 17) Nutlin 3a (PubChem CID: 216345); 18)
Pf562271(PubChem CID: 11713159); 19) PIK75 (PubChem CID: 9825070); 20) Ponatinib
(PubChem CID: 24826799); 21) WIKI4 (PubChem CID: 2984337); 22)Wp1130
(PubChem CID: 11222830); 23) ZSTK474 (PubChem CID: 11647372)
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1.0 Introduction
One of the challenges to effective cancer treatment is multidrug resistance which decreases
long term survival rate of patients despite advances in cancer therapy [1]. Multidrug
resistance (MDR) is the phenomenon where cancer cells become resistant and
unresponsive to a variety of chemotherapeutic agents. Mechanisms of MDR in cancer
includes activation of DNA repair mechanism, interference in apoptotic signaling
pathways, activation of drug metabolizing enzymes and overexpression of drug
transporters [2]. The overexpression of drug transporters is the most common mechanism
of MDR and is widely studied [3]. Underlying this type of MDR is active efflux of variety
of structurally and functionally unrelated pharmacological agents from cells. The
superfamily of drug transporters called ATP binding cassette (ABC) transporters have been
implicated to confer resistance to clinically active drugs especially P-glycoprotein (Pgp/ABCB1), breast cancer resistant protein (BCRP, ABCG2) and multidrug resistant
protein 1 (MRP1/ ABCC1)[4, 5]. These drug transporters actively pump out
chemotherapeutic drugs reducing the intracellular levels of drugs and consequently drug
efficacy. These transporters are also impediments in the treatments of neurological
disorders , epilepsy as they are present at the brain blood barrier and extrude xenobiotics
from the CNS[6]. The expression of MRP1 in peripheral blood mononuclear cells of
children who have intractable epilepsy is increased as compared to children with epilepsy
controlled by anti-epileptic drugs (AED) and normal children [7].
The ABC transporters are classified into seven subfamilies (A through G) based on their
sequence homology [8]. The mammalian ABC transporters are made up of four domains
often encoded as a single polypeptide (e.g. P-gp) but are sometimes two polypeptides that
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form homodimers (e.g. ABCG2) or heterodimers (e.g. TAP1/TAP2) [9]. MRP1 and several
ABCC homologs have a five-domain structure with two nucleotide binding domains
(NBDs) and 17 transmembranes in three membrane spanning domains (MSD0, MSD1, and
MDS2) [10].
The NBDs each contain three key motifs i.e. Walker A and B motifs characteristic of Ploop ATPases and an “active transport” signature motif common to all ABC proteins [9].
Transport by MRP1 (and other ABC transporters) is driven by the binding and hydrolysis
of ATP, which promotes the required protein conformation changes that aids solute
translocation. The two NBDs form a “sandwich” dimer, with two ATP molecules
sandwiched in the dimer interface. In the ‘sandwich dimer’ the two ATP-binding sites
comprise of the Walker motifs of one NBD and the active transport signature motif of the
other [9]. The ATP-binding sites of MRP1 are functionally nonequivalent. NBD1 has a
higher affinity for ATP (but very low ATPase activity) whiles NBD2 has a greater capacity
for ATP hydrolysis. MRP1 also has composite substrate-binding sites which permits both
cooperativity and competition between various substrates [11].
MRP1 ( ABCC1) was first reported by Cole and colleagues to mediate resistance to
doxorubicin, etoposide and vincristine [5]. MRP1 is ubiquitously expressed in normal
tissues with elevated expression in kidney, lungs, thymus, cardiomyocytes and placenta
with lower expression in colon, brain, small intestine and peripheral blood mononuclear
cells [11,12]. The expression level of MRP1 can still vary between different cell types in
the same tissue. The activity of MRP1 unlike P-gp is not limited to the efflux of xenobiotics
but also endobiotics and other physiological substrates. As such it influences physiological
processes such as transport of inflammatory mediators (extrusion of leukotriene) and
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defense against oxidative stress (transport of glutathione and glutathione conjugates).
Additionally, substrates of MRP1 and P-gp differ by their chemical properties. MRP1
mostly transports organic anions, many of which are conjugated with glutathione (GSH, gGlu-Cys-Gly), glucuronic acid, or sulfate whereas P-gp recognizes unconjugated
hydrophobic substrates [13].
Due to its protective roles, MRP1 expression is also elevated in cells with specialized
barrier functions including choroid cells and capillary endothelial cells. MRP1 is located
on the basolateral membrane of these polarized cells. MRP1 expression is elevated in
rapidly proliferative cells such as reactive type II pneumocytes in lungs; and physiological
barriers such as brain blood barrier(BBB) [14], blood testes [15], blood placental [16]. The
overexpression of MRP1 in cancer cells can affect pharmacokinetic parameters of drug
absorption, distribution, metabolism, excretion and toxicity (ADMET) [17]. Elevated
levels of MRP1 confers resistance to various natural products and anticancer drugs such as
vinca alkaloids, anthracyclines, epipodophyllotoxins [4].
Not much is known about modulators of MRP1 at clinical trials. Although P-gp has been
studied well, no P-gp modulator has been successful at clinical trials. This is mainly
attributed to toxicity related issues and the fact that patients are not selected based on tumor
expression of P-pg. To fully understand and determine the impact of ABC transporters on
multidrug resistance in clinical trials, subpopulation of patients with ABC transporters as
the main mechanism of multidrug resistance should be used. Identification of modulators
of MRP1 and understanding fully the physiological and pharmacological consequences of
doing so is of great interest due to its potential benefits in the treatment of drug resistant
malignancies.
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Previously, we developed, optimized and validated a high content imaging-based efflux
assay to profile drug interactions with MRP1 [18] using calcein-AM. This assay was more
robust and efficient as opposed to more traditional assays such as flow cytometry. This
assay identified 12 novel MRP1 inhibitors after screening of a 384 unique anticancer
library. Furthermore, the adaptation of this assay using doxorubicin as a fluorescent probe
identified 28 inhibitors which included 10 of 12 inhibitors discovered previously with
calcein-AM assay as well as 18 MRP1 inhibitors that were missed by the calcein-based
screening [19]. The rationale for using doxorubicin was to take advantage of the wide range
of the probe and multiple substrate nature of MRP1. Based on the promiscuity of MRP1
substrate binding sites, we tested the hypothesis that using CRO-9 as a fluorescent reporter
substrate, which is different in size and shape from doxorubicin and calcein-AM may
identify new inhibitors. The screening of a 386 anticancer library with CRO-9 identified a
total of 50 MRP1 inhibitors including 19 inhibitors that have not been previously reported
as inhibitors. The remaining 31 inhibitors included 10 out of 12 compounds identified with
calcein-AM and 17 out of 18 compounds exclusive to doxorubicin- based screening of the
same library .We verified the inhibitory activity of the identified compounds exclusive to
CRO-9 using flow cytometry and vesicular transport assays. The ability of some selected
compounds to reverse the resistance of an MRP1-overexpressing MDR cancer cell line is
also demonstrated.
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2.0 Materials and methods
2.1 Chemicals
CRO-9, doxorubicin, adenosine monophosphate (AMP), adenosine triphosphate (ATP),
estradiol 17-(β-D-Glucuronide) (E217βG), poly-D-lysine, thiazolyl blue tetrazolium
bromide (MTT) were procured from Sigma-Aldrich (St. Louis, MO). MK571 was acquired
from Cayman Chemical(Ann Arbor, MI) and [6,7-3H]E217βG (49.9 Ci mmol–1) from
PerkinElmer (Waltham, MA). Anti-cancer compound library consisting of 386 anti-cancer
small molecules under clinical trials for 12 different types of cancers was acquired from
Selleck Chemicals (Houston, TX)

2.2 Cell lines and cell culture
H69 and H69AR cells were purchased from ATCC (Manassas, VA). HEK293T cells were
provided by Dr. Adam Hoppe (South Dakota State University, Brookings, SD). HEK293
and H69 cell lines were cultured in DMEM (GE Healthcare, Marlborough, MA) and RPMI
1640 (ATCC), respectively, supplemented with 10% fetal bovine serum. Cells were grown
in a humidified incubator maintaining 5% CO2 at 37°C. H69AR cells were exposed to 0.8
µM doxorubicin monthly and cultured drug-free for a week before use.

2.3 Screening for MRP1 inhibition via automated image acquisition and analysis
The assay was developed and optimized using H69 and doxorubicin resistant cell line
H69AR. CRO-9 was used as the fluorescent substrate and MK571 as the positive control.
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Both cell lines were seeded at 6 × 104 cells per well in 100 µL culture medium in 96-well
optical-bottom plates with polymer base (ThermoFisher Scientific, Waltham, MA) coated
with poly-D-lysine (Sigma-Aldrich, St. Louis, MO) and allowed to attach overnight.
Culture medium was replaced with 80 µL of serum-free medium. Prior to incubation with
CRO-9, 10 µL of test compounds (10 µM final concentration), DMSO (0.2% final
concentration) as negative control, or MK-571 (50 µM final concentration) as positive
control were added and incubated for 30 min. A total of 10 µL of CRO-9 (0.25 µM final
concentration) was added and incubated for an additional 30 min. Treatment was removed
and 100 µL of PBS containing 10mM HEPES and 4.5% glucose was added post incubation.
Images were obtained using an ImageXpress Micro XLS Widefield High-Content Analysis
System (Molecular Devices, Sunnyvale, CA) equipped with a 0.70 numerical aperture 60×
objective. Eight images (4 bright field and 4 fluorescent) were taken for each well.
Fluorescent images were acquired using a texas red filter with excitation and emission
wavelengths of 562/40 nm and 624/40 nm, respectively, with an exposure time of 100 ms.
Both negative and positive controls were included in every two columns to account for
fluorescence decrease across the 96-well plate due to gradual decrease in intracellular
accumulation of probe over time. intracellular int fluorescence. Screening was performed
in 3 independent experiments. Fluorescent images were analyzed using the MetaXpress
software (version 5.10.41, Molecular Devices). Segmentation of fluorescent objects on the
texas red channel was achieved using a custom application module based on the ‘Find
Blobs’ module. The custom module enables differentiation of fluorescent accumulation
from background and artifacts via segmentation masks based on set parameters for object
size.
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2.4 Doxorubicin accumulation assay using confocal microscopy
Confocal microscopy was used to confirm inhibition of MRP1 mediated doxorubicin
efflux. HEK293T cells were plated on poly-D-lysine-coated cover glass placed in a 6-well
plate at a density of 5 × 105 cells/well in 2 mL culture medium. Cells were transiently
transfected with an MRP1-GFP expression vector after 24 hours using jetPRIME
Transfection Reagent (Polyplus-transfection SA, Illkirch, France) according to the
manufacturer’s protocol. After 48 hours, cells were pre-treated with 10 µM test compound
for 30 min, before incubation with doxorubicin (10 µM) for 1 h. Cells were maintained in
buffer (4.5 % glucose, 10mM HEPES, PBS containing Ca2+ and Mg2+ ) as intracellular
fluorescence was visualized using a iMIC digital microscope (TILL Photonics GmbH,
Gräfelfing, Germany) equipped with a 1.35 numerical aperture 60x oil-immersion
objective. Excitation was done at 488 nm for GFP and doxorubicin, with emission bands
of 475/42 and 605/64 nm, respectively. Images were processed using ImageJ (NIH,
Bethesda, MD).

2.5 Flow cytometry-based CRO-9 accumulation assay
MRP1 mediated efflux of CRO-9was determined in the presence/absence of test
compounds using flow cytometry. This was to quantitatively affirm the inhibition activity
of drugs identified in the screening assay . H69AR cells were prepared in serum-free
culture medium to a density of 7 × 105 cells/mL. One mL of cells was incubated with test
compounds (10 µM) at 37 °C for 10 min after which 0.25 µM of CRO-9was added for an
additional 30 min. DMSO concentration was maintained at 0.2% (v/v). Efflux activity of
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MRP1 was stopped by adding ice-cold PBS buffer. Cells were then collected, washed with
cold PBS and resuspended in ice-cold PBS containing 1% formaldehyde. Intracellular
fluorescence of CRO-9was detected by BD Accuri C6 flow cytometer (BD Biosciences,
San Jose, CA) equipped with 488nm and > 670nm for excitation and emission respectively.
Fluorescence intensity was collected as mean of 10,000 events. Treatments were performed
in duplicate and repeated in 3 independent experiments.

2.6 Membrane vesicle preparation
Membrane vesicles were prepared as described in Loe et al., [20] with modifications.
Frozen cell pellets of HEK293/pcDNA 3.1 and HEK293/MRP1 were thawed and
suspended containing 50 mM Tris.HCl, pH 7.4, 250 mM sucrose, 0.25 mM CaCl2, and 1x
complete protease inhibitors (Santa Cruz Biotechnology, Dallas, TX). Cell disruption was
achieved via nitrogen cavitation at 450 psi for 5 min. The resultant lysates were
supplemented with 1mM EDTA and centrifuged at 500 × g at 4 °C for 10 min. The
supernatant was collected twice by resuspending cell pellets and repeating centrifugation.
Pooled supernatant was layered over 35% (w/w) sucrose containing 10 mM Tris.HCl,
pH7.4, and 1 mM EDTA and centrifuged at 25,000 rpm at 4 °C for 1 h in a SW28 rotor
(Beckman Coulter, Brea, CA). The opaque membrane interface formed was collected and
washed twice by ultracentrifugation. The membrane pellet obtained was further
resuspended in transport buffer (50 mM Tris.HCl, pH 7.4, and 250 mM sucrose) and passed
20 times through a 27-gauge needle for vesicle formation. Protein concentration was
determined using Quick Start Bradford Protein Assay (BioRad, Hercules, CA).
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2.7 Membrane vesicular transport assay
A rapid filtration technique was used to measure the ATP-dependent transport of
[3H]E217βG into MRP1 enriched inside-out membrane vesicles [20]. The vesicles (2 µg
protein) were incubated with 400 nM/20 nCi [3H]E217βG for a minute at 37°C in a 30-µL
reaction mixture containing 4 mM AMP or ATP, 10 mM MgCl2, and test compound in
transport buffer (250 mM sucrose and 50 mM Tris-HCl, pH 7.4). Total DMSO
concentration was kept at 0.3%. Reaction was stopped by the addition of ice-cold buffer
and resulting mixture transferred to a 96-well MultiScreenHTS-FB plate (EMD Millipore,
Billerica, MA). Filter membranes were washed 4X with 200 µL ice-cold suspension buffer
under vacuum aspiration. Radioactivity retained on the membranes was measured with TriCarb 4810TR liquid scintillation counter (PerkinElmer, Waltham, MA). ATP-dependent
uptake was calculated by subtracting the uptake in the presence of AMP from the uptake
in the presence of ATP. Treatments were performed in triplicates.

2.8 Drug sensitivity Assay
The sensitivity of H69 and H69AR cells towards multiple chemotherapeutic drugs
(vincristine and SN-38) and the ability of test compounds to reverse the resistance of
H69AR cells against these drugs were analyzed using the MTT colorimetric assay. H69
and H69AR cells were seeded in 96-well plates (CellBIND®, Corning) at 2.5 × 104 cells
per well in 100 µL culture medium and allowed to attach overnight. The cells were
pretreated with 50 µL of test compounds in culture medium and incubated for an hour.
Subsequently, 50 µL of cytotoxic drugs (vincristine and SN38) at varying concentrations
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was added to the cells. Final DMSO concentration was maintained at 0.2%. Cells were
further incubated for 96 h. At the end of the incubation period, 100 µL of culture medium
was carefully removed and cells were treated with MTT (0.5 mg/mL) for 4 h. The formazan
crystals were dissolved by the addition of 100 µL of 15% SDS containing 10 mM HCl and
absorbance at 570 nm were recorded using a Hidex Sense Beta Plus plate reader (Turku,
Finland). Treatments were performed in triplicates and repeated three times.

2.9 High content screening data analysis
The MetaXpress software was used for analysis. The mean fluorescent intensity of each
well was obtained from averaging the fluorescent intensities of the segmentation mask of
4 captured images. The use of segmentation mask prevents the inclusion of background
fluorescence as cells are defined. The relative inhibition of each test compound on CRO9efflux was determined for each well using the following equation:
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 𝑋 𝑇 − 𝑋 𝐶𝑅𝑂 − 9

𝑋 𝑀𝐾-571 − 𝑋 𝐶𝑅𝑂 − 9

× 100 ,

where X represents the average fluorescent intensities and T represents the test compound.
Both positive and negative controls were placed in every two columns and used for the
determination of the percent inhibition for compounds within the same columns. The Z’factor, a parameter commonly used to infer the versatility and variation of an assay [21]
was determined with the following equation:
𝑍 ′ -𝑓𝑎𝑐𝑡𝑜𝑟 = 1 − 3 𝜎 𝑀𝐾-571 + 𝜎 𝐶𝑅𝑂 − 9
9

,

𝜇 𝑀𝐾-571 − 𝜇 𝐶𝑅𝑂 −
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where σ and μ represent the standard deviations and means, respectively.
2.10 Statistical analysis
Statistical analyses were performed using GraphPad prism (GraphPad Software, San
Diego, CA). The differences between mean values were analyzed using linear mixed model
analysis. Sidak correction was applied for multiple comparisons. For all analyses,
differences were considered significant at P value lower than 0.05.
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3.0 Results
3.1 Assay development and optimization
We recently reported the development of an imaging-based high content assay for
screening for MRP1 inhibitors. This system is more robust and efficient as compared to a
fluorescent microplate reader or flow cytometer as it eliminates background fluorescence
or artifacts by using the custom module to identify cells. This assay originally developed
with calcein-AM [18] had been adapted using doxorubicin [19]. The assay using
doxorubicin as a fluorescent reporter identified more inhibitors than calcein-AM after
screening the same anti-cancer library. MRP1 as a drug transporter has multiple binding
sites thus identification of inhibitors is limited to the fluorescent probe used. In this study,
High-Content Screening System, which employs advanced image analysis and quantitation
tools, was used to develop an imaging-based high-throughput efflux assay for MRP1using
CRO-9 as probe. H69 cell line and its MRP1-overexpressing derivative H69AR cell line
were used for the development and optimization of this assay. The parental H69 cells are
expected to have higher intracellular accumulation of CRO-9 due to low expression of
endogenous MRP1 as compared to H69AR. However, H69AR is expected to have lower
intracellular accumulation of CRO-9 due to the efflux activity of MRP1 under similar
experimental conditions. For optimization of the assay, both concentration and time
dependent accumulation of CRO-9 were studied in both cell lines.
As shown in Figure 3.1A, increased concentrations of CRO-9 yielded an increase in
intracellular fluorescence. The intracellular accumulation of CRO-9 was remarkably higher
in the parental H69 as compared to the H69AR in all tested concentrations. To confirm that
the difference in fluorescence accumulation observed in both cell lines were due to MRP1
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activity, MK571, an MRP1 inhibitor was introduced. MK571 did not affect CRO-9
accumulation regardless of the incubation duration in H69 cell line (Figure 3.1B). In
contrast, MK571 significantly increased intracellular fluorescence in H69AR by
approximately 6-fold at 30 minutes of incubation as indicated in Figure 3.1C.
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Figure 3.1 Concentration- and time-dependent accumulation of CRO-9 in H69 and
H69AR cells.
A. H69 and H69AR cells were treated with CRO-9 at various concentrations (10–300 nM)
for 1 h. Representative images of CRO-9 treatment at 30, 100, and 300 nM are shown. The
average fluorescence intensities derived from the fluorescent images were graphed and
shown on the right. B. H69 cells were treated with 250 nM CRO-9 in the absence and
presence of 50 µM MK571 for 30–90 min. Representative images of CRO-9 treatment at
30, 60, and 90 min are shown. C. H69AR cells were treated with 250 nM doxorubicin in
the absence and presence of 50 µM MK571 for 30–120 min. Representative images of
CRO-9 treatment at 30, 60, and 90 min are shown. Data are representative of two
experiments and shown as mean ± SD (n=3).

3.2 Anti-cancer compound library screening for MRP1 inhibitors
After optimization of the high content assay with CRO-9, a 386 anti-cancer library under
clinical trials of 12 different cancer types was screened for inhibitors of MRP1. Screening
was done in a 96-well format in triplicates. Treatment with 50 µM MK571 (a commonly
used MRP1 inhibitor) was considered as 100%MRP1 inhibition for calculating percent
inhibition for the test compounds. Three independent screening experiments were done
using the 96-well format. The relative MRP1-inhibitory activities of the test compounds
from three independent experiments are represented as a 3D scatter plot (Fig. 3.2). The
assay had good reproducibility with a correlation range of 0.72-0.78 between any two given
experiments. The quality and performance of the assay were also assessed by calculating
the Z’-factor from the experiments. The average Z’-factor across all plates was 0.51,
indicating a good assay performance. A positive hit was defined as a compound with ≥
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50% mean percent inhibition. With this threshold value, we identified 50 hit compounds
indicated by orange dots in Figure 3.2. Ten compounds out of the 50 were identified in
previous studies in our lab using calcein-AM [18] and doxorubicin [19] as fluorescent
reporters. Seventeen out of the remaining forty compounds were exclusive to studies using
doxorubicin as fluorescent reporter. The twenty-three compounds that had not been
identified in either studies were chosen for further studies.
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Figure 3.2 Performance of the imaging-based MRP1-mediated CRO-9 accumulation
screening assay.
Screening of the anti-cancer compound library was performed in three independent
experiments at a compound concentration of 10 µM. The relative inhibitory activities of
each compound were calculated and displayed as a 3D plot. Orange dots represent
compounds with a mean percent inhibition of ≥50%. The table below the plot shows
correlation coefficients between any two experiments. 3D scatter plot was generated using
SigmaPlot 12.0 and correlation coefficients were calculated using MS Excel.

3.3 Validation of MRP1 inhibitors
To qualitatively evaluate compound effect on doxorubicin efflux, HEK293T cells were
transiently transfected with MRP1-GFP vector and the inhibitory effect of the test
compounds on MRP1 activity was visualized using confocal microscopy. As shown in
Figure 3.3A, cells treated with DMSO showed high doxorubicin accumulation in the nuclei
of non-transfected cells, while cells expressing MRP1-GFP displayed very low
doxorubicin accumulation. MRP1-mediated efflux of doxorubicin was reduced by MK571
(50 µM), which was used as the positive control. All the test compounds (10 µM) induced
doxorubicin accumulation in MRP1-expressing cells to a certain extent, ranging from
strong, moderate to mild. Drugs such as, BIBR 1532, bosutinib, WP1130 and nutlin-3
showed strong inhibition, while GSK11202122, PF562271, ZSTK474, ponatinib and
NU7441 showed moderate to mild inhibition. For a more quantitative assessment of hit
compounds, flow cytometry was done. To this end H69AR cells were pre-treated with the
test compounds for 10 minutes prior to incubation with CRO-9 for 30 minutes. As shown
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in Figure 3.3B, MK-571 at 50 µM enhanced doxorubicin accumulation in H69AR cells by
3-fold. All hit compounds (10 µM) except evista, gefitinib, KU-0063794, and NU7441
significantly increased CRO-9 accumulation in H69AR cells by 1.6–2.8-fold.
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Figure 3.3 Validation of MRP1-inhibitory activity of identified hit compounds.
A. HEK293 T cells transiently transfected with MRP1-GFP (green) were pre-treated with
10 µM test com- pounds for 30 min, before treatment with doxorubicin (red) at 37 °C for
1 h. Images were acquired using confocal microscopy. GFP and doxorubicin were excited
at 488 nm, and detected at 475/42 and 605/64 nm, respectively. B. H69AR cells were pretreated with 50 µM MK571 or 10 µM test compounds for 10 min before treatment with
250 nM CRO-9 at 37 °C for 30 min Fluorescence intensities of intracellular doxorubicin
were detected using flow cytometry, with excitation and emission wavelengths of 488 and
610/20 nm, respectively. Data are combined from two experiments and presented as mean
± SEM. *, p value lower than 0.05 compared with control

3.4 Effects of hit compounds on MRP1 mediated E217βG vesicular uptake
Due to the essential physiological role of MRP1 in tissue defense, we were interested in
evaluating our hits compounds on MRP1-mediated transport endogenous MRP1 substrates.
For this purpose, we employed membrane-based vesicular uptake assay for E217βG, a
glucuronide conjugate and a prototypical physiological substrate of MRP1 Membrane
vesicles were prepared from HEK293/pcDNA 3.1 and HEK293/MRP1 cells. The uptake
of [3H] labelled E217βG was measured to evaluate the effect of potential MRP1 modulators
on E217βG efflux. As shown in Figure 3.4, ATP-dependent uptake of [3H]E217βG into
HEK293/pcDNA3.1 (vector control) membrane vesicles was less than 1% of uptake by
HEK293/MRP1 membrane vesicles. Transport of [3H] E217βG into HEK293/MRP1
membrane vesicles was reduced by 94% with 10 µM MK571. Among the test compounds,
evista, GSK1120212, MK-0752 and WIKI4 inhibited [3H]E217βG uptake by more than
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50%, while CW069, gefitinib, KU-0063794, KU-55933, and LY2603618 showed little to
no inhibition of [3H]E217βG transport uptake into HEK293/MRP1 membrane vesicles.

Figure 3.4 Effects of test compounds on [3H]E217βG uptake into MRP1 expressing
membrane vesicles.
Membrane vesicles were prepared from stable HEK293/ pcDNA3.1 and HEK293/MRP1
cells. Membrane vesicles (2 µg protein) were incubated with 10 µM test compounds.
Reactions were performed using 400 nM/20 nCi [3H]E217βG at 37 °C for 1 min.
Radioactivity retained on membrane vesicles was quantified using liquid scintillation
counting. Data were combined from two experiments and presented as mean ± SEM, * p
value lower than 0.05 compared with control.
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3.5. Resistance reversal by selected MRP1 inhibitors
Multidrug resistance is a major barrier to the success of chemotherapy. We therefore
wanted to verify if the identified anticancer hit compounds had the ability to reverse
resistance mediated by MRP1. Drugs that had this ability could be useful in clinical
combinatorial therapies. Six potential drug hits (GSK650394, KU-0063794, LY2603618,
MK0752, NU7441, ZSTK474) were selected for reversal studies based on available data.
The ability of test compounds to reverse MRP1 mediated resistance in H69AR lung cancer
cells against vincristine and SN38 was evaluated. These cytotoxic agents are known
substrates of MRP1 with different chemical classifications and mode of actions.
First, concentration-response was conducted for selected drug hits to evaluate the
cytotoxicity profile of these compounds in H69AR (data not shown). Selected hit
compounds at non-cytotoxic concentrations were then administered in combination with
increasing concentrations of vincristine or SN38 to determine the ability to reverse
resistance in H69AR cells. As shown in Figure 3.5 MRP1-over- expressing H69AR cells
(solid red) showed MDR and as expected exhibited much lower sensitivity towards each
of the cytotoxic cancer drugs than H69 cells (dotted red). IC50 values and fold resistance of
the parental H69 and the MRP1-overexpressing derivative H69AR cells treated with
vincristine or SN38 with or without the selected compounds are presented in Table 3.1.
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Table 3.1 The effects of selected MRP1 inhibitors on the IC50 values of vincristine and
SN38
Cell line/Treatment

Vincristine
IC50 a (nM)

SN38
Fold resistance

IC50 a (µM)

b

a

H69

0.861 ± 0.003

1.00

H69AR

23.35 ± 3.4

H69AR + MK571 10 µM

Fold resistance
b

1.00

27.11

0.0030 ±
0.0004
0.71 ± 0.04

9.33 ± 1.43

10.83

0.28 ± 0.04

94.89

H69AR + GSK650394 10
µM
H69AR + KU-0063794 0.1
µM
H69AR + LY2603618 10 µM

14.96 ± 0.77

17.37

0.45 ± 0.05

151.57

12.55 ± 1.11

14.58

0.46 ± 0.04

153.83

11.12 ± 0.30

12.92

1.84

H69AR + MK-0752 10 µM

11.98 ± 0.23

13.92

0.0055 ±
0.0006
0.52 ± 0.12

H69AR + NU7441 10µM

13.04 ± 0.52

15.14

0.389 ± 0.001

129.66

H69AR + ZSTK474 2 µM

11.76 ± 0.82

13.66

0.03 ± 0.01

9.74

236.90

171.96

Mean ± SEM of n ≥ 3 independent experiments.

b

Fold resistance is the ratio between IC50 value of each treatment and IC50 value of

vincristine and SN38 alone in H69 cells.
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Figure 3.5 Reversal of drug resistance towards vincristine and SN38 in H69AR cells by
selected MRP1 inhibitors.
A. H69 and H69AR cells were treated with vincristine at increasing concentrations in the
absence and/or presence of selected MRP1 inhibitors. B. H69 and H69AR cells were
treated with SN38 at increasing concentrations in the absence and/or presence of selected
MRP1 inhibitors. A and B. MK571, GSK650394, LY2603618, MK-0752, NU7441, were
at 10 µM, KU-0063794and ZSTK474were at 0.1 µM and 2 µM respectively. Cell viability
was evaluated with MTT after 72 h. Data are representative of three experiments and
presented as mean ± SD (n = 3).
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Figure 3.6 Chemical Structures of the selected 23 hit compounds
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4.0 Discussion
Chemotherapy is the prevalent form of treatment for advanced stages of most types of
cancer. Factors affecting the success of chemotherapy include multidrug resistance (MDR)
and toxicity. MDR is known to be a major cause of relapse in chemotherapy. Energy
dependent efflux of anticancer drugs by mainly P-gp, MRP1 and BCRP have been reported
to be a significant contributing factor to the development of MDR due to their key roles in
drug disposition of anticancer therapeutics [3, 22]. Conventional anticancer drugs such as
doxorubicin, vincristine, etoposide, methotrexate and carboplatin target basic and essential
cellular processes in their mechanism of action. Thus, conventional chemotherapeutics are
not specific and results in increased toxicity in patients. Current and emerging
chemotherapeutics are drugs that show specificity in cancer cell type and often target
specific signaling pathways associated with specific cancers. However, with the ability of
drug transporters such as MRP1 to interact and affect the bioavailability of a broad
spectrum of drugs, it is essential to profile interactions of new and emerging
chemotherapeutics with drug transporters. In cancers such as childhood neuroblastoma,
ovarian cancer [23], acute lymphoblastic leukemia [24], the overexpression of MRP1 has
been linked to the poor survival rates of patients. Extensive literature on MRP1 also
supports the potential use of MRP1 as a biomarker in non-small cell lung cancer (NSCLC)
[25].
Current strategies to overcome ABC transporter mediated MDR include the coadministration of transporter inhibitor with chemotherapeutics (combination therapy) or
the use of anticancer drugs that are not substrates of MRP1. Several modulators have been
developed and investigated over time for their inhibitory activity against MRP1-mediated
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transport. Drugs such as indomethacin, probenecid, MK571, and ONO-1078 have been
shown to inhibit MRP1 in vitro but the clinical significance has been uncertain due to
toxicity and specificity related issues [26]. No potent and safe MRP1 modulator has been
developed yet. In this study we investigated the interaction of MRP1 with a unique library
of anti-cancer compounds currently under clinical trials targeting 12 types of cancers.
MRP1 inhibitors from this library has the potential of being used to reverse MRP1
mediated drug resistance in cancers where MRP1 is significantly overexpressed. They can
also be used to improve efficacy of other known anticancer agents which are substrates of
MRP1.
For this study, we successfully developed and validated a high content imaging-based
uptake assay for MRP1 transport activity using CRO-9 as a fluorescent reporter substrate.
We are the first to discover CRO-9 as a substrate of MRP1 and develop a novel assay using
this dye. Screening of a 386 unique anticancer library with CRO-9, we identified 23 MRP1
inhibitors which were missed by a similar assay using calcein-AM or doxorubicin. The
assay exhibited a high correlation (0.72-0.78) between any two experiments among the
three independent screening experiments. The high quality, performance and range of this
screening assay were demonstrated by a Z’-factor of 0.51 across all plates. High content
imaging used in this study offers an advanced image analysis tools which enables the
elimination of non-specific and background fluorescence. The assay also allows the
simultaneous detection of cell-permeable, non-toxic and potent inhibitors. Majority of
inhibitors identified previously from the 386-unique anticancer library using either calceinAM or doxorubicin as fluorescent reporter were also identified using CRO-9. With
extensive biochemical and structural literature suggesting that MRP1 has multiple distinct
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substrate binding sites [27, 28], our data implies that CRO-9 may have overlapping binding
sites with calcein-AM and doxorubicin and an additional exclusive biding site as well.
These differences observed can be due to structural differences between CRO-9,
doxorubicin and calcein-AM.
Among the 50 hit compounds identified as MRP1 inhibitors in this study, 10 compounds
were common with studies using calcein-AM based screening assay and doxorubicin. An
additional 17 compounds including alisertib and amutavinib which were reported for the
first time to interact with an ABC transporter using doxorubicin were also identified using
CRO-9. Thus, we focused on characterization of the 23 hit compounds exclusive to CRO9. Among the hit compounds exclusive to CRO-9, Nutlin 3, ZSTK474, ibrutinib and evista
has been reported to inhibit the activity of MRP1 transport [29, 30, 4, 31]. Out of the 23
inhibitors identified, 19 have not been previously reported to inhibit the transport by MRP1.
Nutlin 3a an enantiomer of nutlin 3 has been reported to affect the P-gp and BCRP mediated
transport but not MRP1 [29, 32]. In validating our hit compounds as MRP1 inhibitors, both
cell-based assays and vesicular transport assays were employed. Nine drugs (AUY922,
CW069, gefitinib, GSK650394, ibrutinib, KU55933, LY2603618, WP1130 and ZSTK474)
significantly affected MRP1 mediated transport in cell-based assays measuring CRO-9
efflux but did not affect MRP1 mediated uptake of E217βG in enriched membrane vesicles.
This demonstrated the substrate selective inhibition ability of some compounds identified
as inhibitors in this study. Compounds that show substrate selective inhibition of MRP1
may be useful in specialized treatment of MDR tumors.
Six of the inhibitors identified in this study (GSK650394, KU-0063794, LY2603618,
MK0752, NU7441 and ZSTK474) were evaluated for their ability to reverse MRP1
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mediated resistance of MRP1-overexpressing lung cancer cell line (H69AR) against
vincristine and SN38. We also sought to examine whether reversal of resistance by selected
drugs were substrate specific. Vincristine and SN38 are MRP1 substrates with different
chemical class/family and cellular mechanism. Among the 6 drugs evaluated, LY2603618
and ZSTK474 were the most effective in reversing MRP1- mediated resistance by reducing
fold resistance to vincristine from 27.11 to 12.92 and 13.66 respectively. For MRP1mediated resistance of H6AR to SN38, LY2603618 and ZSTK474 reduced the fold
resistance from 236.90 to 1.84 and 9.74 respectively. LY2603618, a novel MRP1 inhibitor
identified in this study is a Chk (Checkpoint kinase) inhibitor which has been used in 7
clinical trials as of September 20th, 2019 (clinicaltrials.gov) for studying the treatment of
solid tumors, advanced cancer, pancreatic neoplasms [33], and non-small cell lung cancer
(NSCLC) [34]. LY2603618 has been shown to increased cisplatin sensitivity in
osteosarcoma, however the interaction of the drug with ABC transporters including MRP1
has never been reported. LY2603618 in our study successfully reduced fold resistance of
H69R to vincristine by half (reduced from 27-fold resistance to approximately 13-fold). It
also reversed resistance to SN38 almost completely by decreasing the fold resistance from
237-fold difference to 1.8-fold which is similar to the non-resistant parental cell line (H69).
With MRP1 being overexpressed in cancers such as non-small lung cancer [25],
LY2603618 holds great promise in the treatment of subpopulation of NSCLC patients who
have upregulated MRP1 levels.
ZSTK474, a potent phosphoinositide 3-kinase (PI3K) inhibitor identified in this study has
been reported to inhibit P-gp, MRP1 and BCRP [35]. It has been reported to have
synergistic effect when combined with imatinib in multidrug resistant K562/A02 cells [36].
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ZSTK474 has also been shown to reverse MDR resistance in HL60/HL60ADR cells [30]
which is consistent with our findings. In our study, ZSTK474 was much more efficient in
reversing resistance to SN38 (reduced approximately 237-fold resistance to approximately
10- fold resistance) as compared to vincristine (27-fold resistance to approximately 14-fold
resistance).
GSK650394, a serum-regulated kinase 1 (SGK1 inhibitor) which has been investigated for
its potential as therapeutic treatment of prostate cancer [37] and colorectal cancer [38] is
reported for the first time to inhibit and reverse MRP1 mediated resistance of H69AR to
vincristine and SN38. KU-0063794, an mtor inhibitor was able to sensitize H69AR to
vincristine (IC50 reduced from 23.4 to 12.55 nM ) and SN38 (reduced IC50 from 0.71 to
0.46 µM). Interactions of KU-0063794 with ABC transporters has also not been reported.
NU7441 is a potent DNA-PK inhibitor has been reported to inhibit P-gp mediated efflux
of doxorubicin [39] but has not been reported for its inhibitory activity against MRP1.
Another novel inhibitor identified in this study (MK0752) has been in nine phase I /phase
II clinical trial for combination therapies for various cancers (clinicaltrials.gov). For
advanced metastatic breast cancer, the drug is combined with docetaxel whiles
combination with gemcitabine is being done for patients with pancreatic ductal
adenocarcinoma. Although reversal of MRP1 resistance has not been demonstrated,
MK0752 is a known gamma secretase inhibitor that targets the notch signaling pathway
[40]. Some studies have shown that chemotherapy drugs such as doxorubicin induces a
Notch 1 dependent upregulation of MRP1 [41, 42]. In this study, MK0752 sensitized
MRP1-overexpressing H69AR cells to vincristine (reduced IC50 from 23.4 to 11.98 nM)
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and SN38 (reduced IC50 from 0.71 to 0.52 µM). The effect on MRP1 mediated resistance
observed may therefore be due to the effect of the drug on the notch signaling pathway.
In summary, we demonstrated the efficacy of using CRO-9 as a fluorescent reporter in a
high content imaging-based assay to profiling interactions with MRP1. Anti-cancer agents
which were identified as inhibitors have the potential of being used in combinational
therapy to increase the efficacy of other chemotherapeutic drugs. They can also be explored
in treatment of subpopulation of patients with multidrug resistance cancers where MRP1
is prominently expressed.
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RELEVANT CONTRIBUTIONS
1.0 Scope
This chapter entails relevant contributions to other studies in our research group. The
research in this chapter is categorized into two projects. The first project was titled
“Calcitriol and Calcipotriol Modulate Transport Activity of ABC Transporters and Exhibit
Selective Cytotoxicity in MRP1-overexpressing Cells” and published in Drug Metabolism
and Disposition [1]. In this project, the focus of the paper was showing the selective
cytotoxicity of calcitriol and calcipotriol toward MRP1-overexpressing cells which could
be eliminated with MRP1 inhibitor MK571. Data obtained indicated a potential role of
calcitriol and its analogs in targeting malignancies in which MRP1 overexpression is
prominent and contributes to MDR.
The second project, titled “Development of Novel Intramolecular FRET-Based ABC
Transporter Biosensors to Identify New Substrates and Modulators” published in
Pharmaceutics [2]. The objective of the research was to develop a functional recombinant
MRP1 biosensor protein which could determine compound interactions with MRP1. The
clone MRP1-GR-881 was used in screening 40 novel anti-cancer drugs and identified 10
hits that potentially directly interact with MRP1 and could be substrates or modulators.
This provides a valuable tool in profiling of drug libraries for interaction with MRP1.
Knowledge of drug-MRP1 interactions can provide useful information to improve the
efficacy and reduce the toxicity of various therapies.
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Calcitriol and Calcipotriol Modulate Transport Activity of ABC Transporters and
Exhibit Selective Cytotoxicity in MRP1-overexpressing Cells
1.1 Introduction
Collateral sensitivity is a phenomenon in which the development of resistance toward a
cytotoxic agent in the cells simultaneously confers a greater sensitivity to an alternate agent
[3]. The possibility of exploiting collateral sensitivity in cancers where P-gp, MRP1, and
BCRP is overexpressed is garnering heightened interest [3]. The underlying mechanisms
for collateral sensitivity are yet to be delineated but several putative mechanisms have been
proposed, including the generation of reactive oxygen species, change in cellular energy
levels, extrusion of essential endogenous substrate, and membrane perturbation in the
resistant cells [4]. Calcitriol (1, 25-dihydroxyvitamin D3), the active metabolite of vitamin
D3, is a potent hormone which regulates numerous physiologic processes in human body.
Calcitriol is conventionally recognized for its role in bone development via the absorption
of calcium and phosphorous [5]. Accumulating data recently shows other non-skeletal
functions in conditions such chronic kidney diseases [5]. In cancer, multiple evidence from
epidemiologic and preclinical studies suggest that calcitriol reduces cancer risk and
progression. However, evidence from randomized clinical trials has been lacking or
inconclusive [6,7]. Nonetheless, the interest in the use calcitriol for the prevention and
improvement of cancer and other diseases remains high and several large-scale clinical
trials are underway to determine the effects of calcitriol on these major diseases [7].
Calcipotriol, a synthetic derivative of calcitriol is conventionally used in the treatment of
psoriasis. However, it was also recently shown to be effective immunotherapy against
early skin cancer when combined with 5 fluorouracil [8].
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In this paper, the focus of my research and contribution was to confirm that the
hypersensitivity observed in MRP1 over expressive cell lines (H69AR and HEK/MRP1)
after exposure to calcitriol and calcipotriol was due to the transport activity of MRP1.
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1.2 Materials and methods
1.2.1 Chemicals
Calcitriol, calcipotriol, MK571, and vincristine were purchased from Cayman Chemical
(Ann Arbor, MI). Mitoxantrone, poly-D-lysine, thiazolyl blue tetrazolium bromide (MTT),
and verapamil were obtained from Sigma-Aldrich (St. Louis, MO) whiles Ko143 were
purchased from Tocris Bioscience (Avonmouth, Bristol, UK).

1.2.2 Cell Lines and Cell Culture
H69 and H69AR cells were purchased from ATCC (Manassas, VA). HEK293/pcDNA3.1,
HEK293/MRP1, HEK293/P-gp, and HEK293/BCRP were kindly gifted by Dr. Suresh V.
Ambudkar (NIH, Bethesda, MD). HEK293 and H69 cell lines were cultured in DMEM
(GE Healthcare, Marlborough, MA) and RPMI 1640 (ATCC), respectively, supplemented
with 10% fetal bovine serum. H69AR cells were monthly exposed to 0.8 µM doxorubicin
and cultured without drug for 1 week before use in experiments. Cells were cultured at
37°C in a humidified incubator set at 5% CO2.

1.2.3 Western Blot Analysis
Cell lysates were prepared in RIPA buffer (Thermo-Fisher Scientific, Waltham, MA)
supplemented with 1× Halt Protease Inhibitor Cocktail (ThermoFisher Scientific). Protein
concentration was determined using Pierce BCA Protein Assay (ThermoFisher Scientific).
Cell lysates (20 µg protein) were electrophoresed on 7.5% Mini-PROTEAN TGX gels
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(BioRad, Hercules, CA) and transferred onto Immobilon PVDF membranes (EMD
Millipore, Burlington, MA). Membranes were blocked for 1 hour at room temperature and
incubated overnight at 4°C with monoclonal anti-MRP1 antibody (QCRL; Sigma) or antiα-tubulin antibody (Sigma-Aldrich) at 1:500 and 1:10000 dilutions, respectively.
Secondary antibody incubation was performed using horseradish peroxidase-conjugated
goat anti-mouse IgG (H + L) (ThermoFisher Scientific) for 1 hour at room temperature.
Target proteins were detected using Western Lightning Plus-ECL, Enhanced
Chemiluminescence Substrate (PerkinElmer) and imaged using a C-DiGit Blot Scanner
(LI-COR Biosciences, Lincoln, NE). For protein expression comparison, protein band
density was analyzed using the Image Studio Lite (LI-COR Biotechnology, Lincoln, NE)
software and corrected for uneven sample loading and transfer using α-tubulin as the
loading control.

1.2.4 Cytotoxicity Assay
Cell sensitivity to test compounds was analyzed using the MTT colorimetric assay.
HEK293 was plated in 96-well plates (CellBIND; Corning) at 5 × 103 cells per well in 100
µl culture medium and allowed to attach overnight. For treatment 100 µl of test compound
of varying concentrations prepared in culture medium was added to the cells. DMSO
concentration was maintained at 0.5%. For the effect of inhibitor on collateral sensitivity,
50 µl of MK571 was added and incubated for 1 hour before the addition of varying
concentration of calcitriol or Calcipotriol. For drug combination treatments in HEK293/Pgp and HEK293/BCRP cells, 50 µl of calcitriol, calcipotriol, or control compounds were
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added and incubated for 1 hour before 50 µl of cytotoxic drugs (vincristine or
mitoxantrone) were added. Cells were incubated for 72 hours. At the end of the incubation
period, 100 µl of culture medium was carefully removed, and cells were treated with MTT
(0.45 mg/ml) for 4 hours. The formazan crystals were dissolved by the addition of 100 µl
15% SDS containing 10 mM HCl and absorbance at 570 nm were recorded using a Hidex
Sense Beta Plus plate reader (Turku, Finland)

1.2.5 Statistical Analysis
Statistical analyses were performed using IBM SPSS Statistics (IBM, Armonk, NY). The
differences between mean values were analyzed using linear mixed model analysis. Sidak
correction was applied for multiple comparisons. For all analyses, differences were
considered significant at P value lower than 0.05.
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1.3 Results
Based on the strong modulatory activity of vitamin D analogues (calcitriol and calcipotriol)
in cell and membrane-based assays, their interaction with MRP1 was further studied.
Preliminary studies showed a hypersensitivity of MRP1-overexpressing cells toward
calcitriol and calcipotriol. Data from the cytotoxic studies revealed a concentrationdependent cytotoxic effect of calcitriol and calcipotriol, calcipotriol, with IC50 values of
11.0 ± 0.7 and 8.9 ± 1.3 µM, respectively, in MRP1 over-expressing H69AR cells (Fig.
4.1A; Table 4.1). However, the IC50 values for calcitriol and calcipotriol in the parental
H69 cells were threefold higher than the resistant cell line. In HEK293/MRP1 cells,
calcitriol and calcipotriol also exhibited a concentration-dependent cytotoxic effect, with
IC50 values of 8.9 ± 1.3 and 6.0 ± 1.8 µM, respectively, which were lower than IC50 values
in parental HEK293/pcDNA3.1 by four-fold. (Fig. 4.1B; Table 4.1).
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Table 4.1 IC50 values derived from cytotoxicity assays
IC50 (µM)a

Assay
Calcitriol

Calcipotriol

29.0 ± 1.2 *

23.9 ± 0.5 *

H69AR (Control)

11.0 ± 0.7

8.5 ± 1.0

H69AR + MK571 (10 µM)

16.4 ± 1.9

15.0 ± 1.1

H69AR + MK571 (25 µM)

35.3 ± 2.2 *

36.3 ± 2.3 **

H69AR + MK571 (50 µM)

61.6 ± 1.0 **

42.4 ± 1.0 **

HEK293/pcDNA3.1

33.4 ± 2.5 **

23.3 ± 3.7 **

HEK293/MRP1

8.9 ± 1.3

6.0 ± 1.8

HEK293/MRP1 + MK571 (10 µM)

11.7 ± 1.1

16.5 ± 0.1

HEK293/MRP1 + MK571 (25 µM)

16.1 ± 0.5 *

23.6 ± 0.6 *

HEK293/MRP1 + MK571 (50 µM)

35.3 ± 4.0 **

27.5 ± 0.2 *

Cytotoxicity
H69

a Mean ± SEM of n = 3 independent experiments
* p < 0.05, ** p < 0.01 significantly different between indicated groups, calculated using
linear mixed model with Sidak post hoc test.

To test whether the observed collateral sensitivity is dependent on MRP1 activity, we
measured the cytotoxicity of calcitriol and calcipotriol treatments in MRP1 overexpressing H69AR and HEK293/MRP1 cells in the presence of 10 and 50 µM MK571
(MRP1 inhibitor). Our results showed that collateral sensitivity of MRP1 over-expressing
cell lines toward calcitriol and calcipotriol can be eliminated by MRP1 inhibitor MK571
(Fig. 4.1; Table 4.1). By using inhibitor at 10 µM (partial MRP1 inhibition) and 50 µM
(complete MRP1 inhibition) the data indicated that collateral sensitivity is proportional to
the amount of active MRP1.
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Figure 4.1 Collateral sensitivity of MRP1-overexpressing cells toward calcitriol and
calcipotriol.
H69 and H69AR cells were treated with increasing concentrations of calcitriol or
calcipotriol in the absence or presence of MK571 for 96 hours. (A). Similar experiments
were performed using calcitriol or calcipotriol in HEK293/pcDNA3.1 and HEK293/MRP1
cells in the absence or presence of MK571 for 72 hour (B). Cell viability was evaluated
with MTT assay. Data are representative of three experiments and expressed as mean 6
S.D. (n = 3).
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1.3.1 Effects of calcitriol and calcipotriol on MRP1 protein expression levels.
To investigate the effect of calcitriol and calcipotriol on the protein expression of MRP1,
western blot was performed on HEK293/MRP1 and H69AR after treatment with 1 µM and
10 µM of both compounds for 48 h. The protein expression levels of MRP1 in both cell
lines were not significantly altered by 1 µM calcitriol and calcipotriol (data not shown).
However, at an increased concentration of 10 µM, calcitriol lowered the protein expression
in H69AR cells but not HEK293/MRP1 as shown in Figure 4.2. However, calcipotriol
treatment at 10 µM concentration did not significantly change MRP1 expression levels in
both cell lines.

128

Figure 4.2 Effects of calcitriol and calcipotriol on protein expression of MRP1
Cells were treated with DMSO, calcitriol, or calcipotriol (10 µM) for 72 hours. (A)
Immunoblot analysis of whole cell lysates prepared from indicated cell lines with indicated
treatments was performed as described in the Materials and Methods section. Data are
representative of three experiments. Mean MRP1 protein expression (S.E.M., n = 3) shown
as a fold change of the DMSO-treated control is shown in (B). Protein band density was
analyzed using the Image Studio Lite (LI-COR Biotechnology) software and corrected for
uneven sample loading and transfer using a-tubulin as the loading control.

1.3.2 Effects of Calcitriol and Calcipotriol on Drug Sensitivity of HEK293/P-gp and
HEK293/BCRP Cells
Previous results had shown that both calcitriol

and calcipotriol did not cause

hypersensitivity in both HEK293/P-gp and HEK293/BCRP cells. Thus, we intended to find
out if calcitriol or calcipotriol had the ability to reverse drug resistance observed in
HEK293/P-gp and HEK293/BCRP against cytotoxic substrates of these cell lines.
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HEK293/P-gp and HEK293/BCRP cells were treated with anticancer drugs vincristine and
mitoxantrone, respectively, in the presence and absence of 10 µM calcitriol and
calcipotriol. Verapamil (25 µM) and Ko143 (1 µM) were used as positive controls for Pgp and BCRP, respectively. As shown in Figure 4.3, HEK293/P-gp and HEK293/BCRP
cells exhibited significant drug resistance as compared with the vector control cell line
HEK293/pcDNA3.1. Treatment with verapamil and Ko143 in HEK293/P-gp and
HEK293/BCRP cells, respectively, reversed the resistance of the cells toward the
anticancer agents. In both cell lines, co-treatment with 10 µM calcitriol significantly
reversed the resistance of the cells to a certain extent. However, no significant reversal was
observed in cells co-treated with 10 µM calcipotriol.
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A

B

Figure 4.3 Effects of calcitriol and calcipotriol on drug sensitivity of HEK293/P-gp and
HEK293/BCRP cells. HEK293/P-gp.
(A) and HEK293/BCRP (B) cells were treated with increasing concentrations of vincristine
and mitoxantrone, respectively, in the absence and presence of calcitriol or calcipotriol (10
µM) for 72 hours. Verapamil (25 µM) and Ko143 (1 µM) were used as positive controls
in HEK293/P-gp and HEK293/BCRP cells, respectively. HEK293/pcDNA cells were
included as negative control for drug resistance. Cell viability was evaluated with MTT
assay. Data are representative of three experiments and expressed as mean 6 S.D. (n =3).
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1.4 Discussion
This study reported for the first time that the active metabolite of vitamin D3, calcitriol,
and its analog calcipotriol, cause selective cytotoxicity in MRP1-overexpressing, but not
P-gp- and BCRP-overexpressing cell lines. Calcitriol was also capable of significantly
reversing resistance of P-gp and BCRP over-expressive cell lines to vincristine and
mitoxantrone respectively. Albeit, calcipotriol did reverse resistance but not significantly
in both cell lines. The addition of MRP1 inhibitor MK571 abolished the hypersensitivity
previously observed in H69AR and HEK/MRP1 cells. This confirmed that the collateral
sensitivity in the cell lines was dependent on the transport activity of MRP1.
Combinatorial approach in cancer therapy which involves combination treatment of
modulators and cytotoxic anticancer agents has been the main approach in targeting ABC
transporter related MDR. Currently, majority of clinical trials using this method has been
conducted using P-gp modulators as P-gp is the most important ABC transporter involved
in MDR. However, these modulators have yielded unsatisfactory results leading to
skepticism about the feasibility and efficacy of modulators/inhibitors in reversing ABC
transporter mediated MDR. [9, 10]. This has garnered sufficient interest in exploiting
collateral sensitivity as a substitute of the use of modulators in clinical trials. Collateral
sensitivity is a phenomenon where drug resistant cells exhibit hypersensitivity to alternate
drugs in comparison with non-drug resistant cells [3, 11]. MRP1-overexpressing H69AR
and HEK293/MRP1 cells exhibited collateral sensitivity toward calcitriol and calcipotriol.
This phenomenon was specific to MRP1-overexpressing cells as we did not observe any
collateral sensitivity in HEK293/P-gp or HEK293/BCRP cells. The selective cytotoxic
activity of calcitriol and calcipotriol to MRP1 over-expressing cells could be attributed to
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a variety of reasons including stimulation of GSH efflux, up-regulation of apoptosis in a
MRP1-dependant manner [12, 13, 14]. In addition, calcipotriol treatment at 1 and 10 µM
did not affect the MRP1 protein levels in HEK293/MRP1 and H69AR cells, however
calcitriol treatment at 10 µM reduced the protein expression level of MRP1 significantly
in H69AR but not HEK293/MRP1. These differences could be due to the physiological
differences in the cell lines as they were derived differently. H69AR cells were derived
from doxorubicin selection of H69 cells and HEK293/MRP1 were obtained through stable
transfection of HEK293 cells.
In conclusion, the main focus of this study was to provide a new perspective to the
application of calcitriol and its analogs in cancer treatment. Specifically, our work suggests
the potential use of calcitriol and its analogs in selectively targeting tumors with the MDR
phenotype conferred by MRP1-overexpression and provides the rational for sequential use
of calcitriol and other anti-cancer agents to circumvent the development of MRP1mediated MDR in clinical chemotherapy. Future work should be focused on designing
calcitriol analogs with improved potency and validating the feasibility of applying the
MRP1-selective effect of calcitriol in vivo.
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Development of Novel Intramolecular FRET-Based ABC Transporter Biosensors to
Identify New Substrates and Modulators
1.0 Introduction
Multidrug resistance protein 1 (MRP1) can efflux a wide variety of molecules including
toxic chemicals, drugs, and their derivatives out of cells. Drug substrates of MRP1 include
anti-cancer agents, antibiotics, anti-viral, and anti-human immunodeficiency virus (HIV)
[15]. Efflux of these drugs can interfere with their sub cellular concentration thereby
reducing drug efficacy. Although drug development involves many stages, time consuming
and costly, a significant number of drugs still fail in clinical trials due to toxicity and
inefficacy related issues [2]. Profiling of drugs with relevant drug transporters can help
eliminate undesirable drugs at early stages of drug development to reduce economic
burden. Profiling drug interactions with MRP1 can identify drugs at risk losing their
efficacy as a result of MRP1 overexpression or useful novel inhibitors useful for clinical
chemotherapy, especially in malignancies where MRP1 is overexpressed.
Previously, we had engineered a two-color MRP1 construct which quantified
intramolecular fluorescence resonance energy transfer (FRET) changes as an index of NBD
conformational changes [16]. The underlying principle is that substrate binding results in
conformational changes in the NDB. To identify novel substrates and modulators of MRP1
by exploiting intramolecular fluorescence resonance energy transfer (FRET), we
genetically engineered six different two-color MRP1 proteins by changing green
fluorescent protein (GFP) insertion sites, while keeping the red fluorescent protein (RFP)
at the C-terminal of MRP1.
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1.2 Materials and methods
1.2.1 Cell Lines and Cell Culture
HEK293T (human embryonic kidney) cell line was donated by Dr. Adam Hoppe (South
Dakota State University, Brookings, SD, USA). Cells were cultured in DMEM (GE
Healthcare, Marlborough, MA) and supplemented with 10% fetal bovine serum. Cells were
cultured at 37°C in a humidified incubator set at 5% CO2.

1.2.2 Detection of MRP1 Localization
HEK293T cells were plated on poly-D-lysine-coated cover glass placed in a 6-well plate
at a density of 5 × 105 cells/well in 2 mL culture medium. Cells were transiently transfected
with the six two-color MRP1 plasmids after 24 hours using jetPRIME Transfection
Reagent (Polyplus-transfection SA, Illkirch, France) according to the manufacturer’s
protocol. After 48 hours, cells were imaged an iMIC digital microscope (TILL Photonics
GmbH, Gräfelfing, Germany) equipped with a 1.35 numerical aperture 60x oil-immersion
objective whiles maintained in buffer (4.5 % glucose, 10mM HEPES, PBS containing Ca2+
and Mg2+). GFP and RFP were excited at 470 nm and 561 nm, respectively. Emissions of
GFP and RFP were correspondingly achieved at 496–530 nm and 573–637 nm. All images
were processed with the ImageJ software (NIH).
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1.2.3 Doxorubicin Accumulation Assay
HEK293T cells were plated at 5 × 105 cells/well in 2 mL of complete medium on a poly
D-Lysine coated coverslip in a six-well plate. After 24 h, the HEK293T cells were
transiently transfected with the six different two-color MRP1 constructs using jetPRIME
transfection reagent according to manufacturer’s protocol. After 48 hours, cells were
treated with 10 µM of doxorubicin and incubated for an hour. Cells were then maintained
in buffer (4.5 % glucose, 10 mM HEPES, PBS containing Ca2+ and Mg2+) and imaged using
an iMIC digital microscope (TILL Photonics GmbH, Gräfelfing, Germany) equipped with
a 1.35 numerical aperture 60x oil-immersion objective. GFP and doxorubicin were excited
at 470 nm wavelength, with emission bands of 480–530 nm for GFP and 570–605 nm for
doxorubicin. RFP was excited at 561 nm with an emission band of 573–637 nm. Images
were processed with ImageJ (NIH).
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1.3 Results and Discussion
1.3.1 Localization and Transport Activity of Two-Color MRP1 Proteins in Live
Cells
Fluorescent protein tags like GFP or RFP are usually fused at the amino-terminal or
carboxyl-terminal, and do not often cause protein folding and trafficking issues. However,
insertion of GFP within the coding sequence of MRP1 could potentially cause problems
with the correct folding and trafficking of MRP1. Although all the two-color MRP1
recombinant proteins showed the expected size, we wanted to verify that both fluorophores
(GFP and RFP) matured properly and that the recombinant MRP1 proteins were folded,
trafficked, and localized properly at the plasma membrane of cells. HEK293T cells were
transfected with cDNA expression vectors encoding different two-color MRP1 proteins,
and confocal microscopy was used to visualize the localization and expression of
recombinant MRP1 proteins. Confocal images in Figure 4.4 indicated that all two-color
MRP1 recombinant proteins except GR-648 localized properly at the plasma membrane.
This construct was not included in further studies. The GR-859 recombinant protein

showed partial mislocalization and intracellular retention, but the recombinant protein was
predominantly localized at the plasma membrane
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Figure 4.4 Localization and expression of two-color MRP1 proteins
HEK-293 (human embryonic kidney) cells were plated on glass-bottom chambered
coverslips.
Fluorescent images were taken using a confocal microscope equipped with a 63× oilimmersion objective. GFP and TagRFP were excited at 470 nm and 561 nm, respectively.
Emission was collected at 480–530 nm for GFP and 580–669 nm for RFP.

To determine if the two-color MRP1 recombinant proteins were functional, their transport
activities were evaluated in live cells by measuring accumulation of the fluorescent anticancer drug, doxorubicin, a well-known substrate of MRP1 [17]. HEK293T cells were
transfected with cDNA expression vectors encoding different two-color MRP1 proteins,
and confocal microscopy was used to visualize the accumulation of doxorubicin (Dox)
inside the cells. Transiently transfected cells are expected to have a mixed population of
cells, transfected and untransfected cells. Transfected cells will express the two-color
MRP1 at the plasma membrane of cells whiles untransfected cells will not. Doxorubicin, a
substrate of MRP1 executes its cytotoxic action in the nucleus where intercalates into
DNA. Thus, cells with a functional MRP1 clone will exhibit a lower intracellular
accumulation of doxorubicin in the nuclei as compared with cells with a non-functional
MRP1. This disparity is due to the efflux of doxorubicin by a functional MRP1.
Doxorubicin fluorescence was very low in cells expressing either GR-638, GR-881, GR888, or GR-905 (Figure 4.5). These results demonstrate that recombinant MRP1 proteins
GR-638, GR-881, GR-888, and GR-905 were functionally active. In contrast, cells
transfected with GR-859 showed high doxorubicin accumulation in the nucleus, indicating
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that this recombinant protein was not functional, despite having the expected size and
proper localization at the plasma membrane.
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Figure 4.5 Doxorubicin (Dox) accumulation assay
HEK293T cells were transiently transfected with six different two-color MRP1 constructs
and incubated for 48 h, after which doxorubicin treatment was done. Images were taken
using a confocal microscope equipped with a 63× objective. GFP and Dox were excited at
470 nm wavelength using an Ar laser, with emission bands of 480–530 nm for GFP and
573–637 nm for Dox. RFP was excited at 561 nm, and its emission was collected at 580–
669 nm. Data were collected from all three channels—GFP, RFP and Dox. RFP and Dox
have significant emission wavelength overlap, explaining the membranous signal seen for
the two-color MRP1 recombinant proteins in the Dox channel.
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FINAL DISCUSSION AND GENERAL CONCLUSIONS
Few ABC transporters are recognized as the key drug transporters to be assessed for their
interaction with new drugs in the drug discovery process. They play a pivotal role in
governing the transit of a broad spectrum of endogenous substrates and drugs across major
organs and physiological barriers [1]. MRP1 is one of the most important ABC transporters
which affects drug distribution. It mediates tissue defense in organs such as lung, skin heart,
kidneys, small intestines and pharmacological barriers like blood brain, blood, testes and
blood placental barrier. In addition to limiting absorption and bioavailability of drugs,
MRP1 also regulates drug elimination into urine and feces [2]. MRP1 is overexpressed in
a diverse range of cancers and has been implicated in poor survival rates in cancers like
acute lymphoblastic leukemia [3], and ovarian cancer [4]. MRP1 may have the widest
spectrum of substrates among all clinically significant ABC transporters (P-gp and BCRP).
Cells that overexpress MRP1 are resistant to a variety of drugs including anthracyclines,
camptothecins, antimetabolites, epipodophyllotoxins and vinca alkaloids [5]. Unlike P-gp,
MRP1 does not transport taxanes [5]. Due to the variability in its clinical significance and
wide substrate range, finding modulators/inhibitors for MRP1 has been more challenging
than P-gp. This may be due to MRP1’s preference of interacting with anionic compounds
[6]. Anionic compounds do not efficiently enter cells due to the hydrophobic nature of cell
walls. As a result, higher doses may be required to attain enough intracellular concentration
for effective inhibition. This increases the likelihood of toxicity in vivo. Organic anion
inhibitors such as probenecid, sulfinpyrazone and indomethacin have been used in vitro to
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inhibit MRP1. However, since their inhibition activity is not specific to MRP1 (includes
all organic anion importers and exporters) they cannot be used clinically as an MRP1
inhibitor [7]. MK571 was initially thought to be a specific inhibitor of ABC (MRP) sub
family of ABC transporters [8]. It was later discovered to inhibit P-gp and BCRP and issues
regarding toxicity has prevented its use in clinical trials [9]. Considerable efforts have been
made to develop inhibitors in order to improve efficacy of anticancer drugs and reduce
transporter mediated MDR. To date, no potent and safe MRP1 modulator has been
developed and tested in clinical trials and efforts to find the ‘ideal’ drug candidate is
ongoing. In this study we investigated the interaction of MRP1 with a unique library of
anti-cancer compounds which is are undergoing clinical trials targeting 12 types of cancers
using a high content imaging-based efflux assay.
Over the years, one of the most widely used cell-based assays for assessment of compound
interaction with ABC transporters has been the fluorescent substrate accumulation assay.
This assay measures the intracellular accumulation of a fluorescent substrate in a
transporter-overexpressing cell line in the presence or absence of test compounds. Assays
using fluorescent probes to evaluate transporter activity are termed as dye extrusion assay
or uptake assays [10]. The accumulation assay has been utilized to study the interactions
of ABC transporters. The general principle of accumulation assays is the fluorometric
determination of intracellular accumulation of a specific probe such as calcein-AM. This
assay has been extensively used to study drug interactions with MRP1 [11, 12] and P-gp
[13]. Calcein-AM easily gets into cells by passive diffusion where it is cleaved by
endogenous cellular esterases to form a hydrophilic non permeable fluorescent compound
[10]. Since calcein-AM is a good substrate of MRP1 and P-gp, it has been used for high
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throughput screening of inhibitors of ABC transporters. Some anticancer drugs such as
doxorubicin and mitoxantrone are fluorescent and thus drug accumulation can be used to
study efflux activity of ABC transporters. Detection and quantification of intracellular
accumulation of fluorescent probe is typically determined by flow cytometry. One of the
major disadvantages using flow cytometry or microplate readout is the inability to exclude
non-specific and background fluorescence which may result in false positives. Also, the
effect of cytotoxic drugs on cell viability cannot be simultaneously detected with inhibitory
activity of the drug.
In recent years, imaging-based high content screening (HCS) using automated microscope
platform has gained increasing popularity in drug discovery field of research. HCS enables
high-throughput imaging of single or multiple biological activities measured as intensity
or spatial localization of fluorescent dyes or proteins in cells. HCS platforms offer unique
advantages over traditional high throughput platforms. The key advantage is its ability to
offer multiple readouts. The readout is typically a fixed endpoint based on object
segmentation. Object segmentation allows definition of cells which minimizes background
noise and facilitates automated analysis. Additionally, this imaging-based uptake assay is
more sensitive than assays based on fluorescence plate reader, which is more suited for
assays done in a homogenous condition. Moreover, cells can be imaged in situ without cell
suspension preparations and multiple washing steps, which increase the processing time
and limit the assay throughput. Furthermore, cell viability and density before and after
treatment can be visually inspected to evaluate compound cytotoxicity, which may
interfere with the assay.
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Our research lab has previously screened a unique anticancer library for MRP1 inhibitors
using a high content imaging-based assay which used calcein-AM as a fluorescent reporter.
This assay identified 12 inhibitors of MRP1 after screening a library of 386 anticancer
agents. Since MRP1 has distinct multiple binding sites, we decided to use other fluorescent
reporters to screen the same library. In this study, our main objective was to develop, and
validate a high content imaging-based efflux assay using doxorubicin and CRO-9 as
fluorescent reporter substrates. We are confident that we are the first research group to use
doxorubicin and CRO-9 as a reporter substrate since there is no available literature
supporting that it has been previously used as a substrate in a high content screening or any
other high-throughput screening assay to identify inhibitors of MRP1. The screening
process in the doxorubicin assay identified a total of 28 inhibitors, which included 10 of
12 inhibitors discovered previously with calcein-AM assay as well as 18 MRP1 inhibitors
that were missed by the calcein AM-based screening. Eleven out of the 18 drugs were
reported for the first time to inhibit MRP1 mediated transport. Notable among the inhibitors
identified using doxorubicin were afatinib, celecoxib, doramapimod, mifepristone, MK2206 and rosiglitazone which showed the ability to reverse MRP1 mediated resistance of
H69AR to vincristine, doxorubicin and etoposide. The drugs showed varied extent of
resistance reversal in all three substrates used. Mifepristone and doramapimod were most
effective in reversal of resistance against vincristine while mifepristone and rosiglitazone
had greater effect on re-sensitizing H69AR cells to doxorubicin. Celecoxib exhibited
selective MRP1 inhibition by completely reversing resistance of H69AR to etoposide but
not having similar effect with vincristine and doxorubicin.
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The assay utilizing CRO-9 further identified inhibitors that were missed by both calceinAM and doxorubicin. A total of 50 MRP1 inhibitors including 19 inhibitors that have not
been previously reported as inhibitors of MRP1 were identified. Though there were some
inhibitors exclusive to the assay with doxorubicin as fluorescent reporter, 23 potential hits
identified by CRO-9 were missed by doxorubicin. Selected drugs (GSK650394, KU0063794, LY2603618, MK0752, NU7441 and ZSTK474) were able to decrease the fold
resistance of H69AR to vincristine and SN38. LY2603618 and ZSTK474 were the most
effective in reversing the resistance of H69AR cells against vincristine and SN38. NU7441
was much more effective in reversing resistance against SN38 as compared to resistance
of H69AR to vincristine. Drugs identified in this study are being studied for the treatment
of various cancers. From our findings some of these drugs hold great potential in the
treatment of subpopulation of patients with malignancies where MRP1 is prominently
expressed.
With new test compounds and pharmacological libraries being developed against a wide
range of diseases, it is important to develop screening methods with high specificity and
reliability for identifying modulators of ABC transporters especially for transporters that
are implicated in multidrug resistance phenotype such as MRP1. Consequently, the use of
just one traditional in vitro screening method may prove problematic as the possibility of
false negative results is increased due to relatively low sensitivity of these methods and
selective inhibitory activity of some compounds.
Taken together, we conclude that this high content imaging-based assay is effective in
identifying novel modulators of MRP1. Based on the International Transporter Consortium
(ITC) recommendation and increased literature supporting the role of MRP1 in the
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development of MDR in cancer, we anticipate that our high content imaging-based assay
will be a great alternative to traditional in vitro methods for pharmaceutical industries
interested in profiling drug interactions with MRP1. In our opinion, there is a lot of
potential in utilizing this high-content imaged assay developed in our laboratory as
doxorubicin and CRO-9 seem to be good fluorescent reporters in screening for MRP1
modulators. This assay also has the potential to aid in the investigation of compound effects
on ABC transporter expression, trafficking, and function. For example, the expression and
trafficking of ABC transporters, and how small molecules affect these cellular events, can
be probed using antibodies in conjunction with reporter substrates described in this paper.
This strategy can be applied on clinically relevant mutants of ABC transporters to screen
for small molecules that can correct anomaly in their expression, trafficking, and
degradation.
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APPENDIX A
Fluorescent substrates of ABC transporters and compounds shown to inhibit efflux
P-gp
BODIPY FL EDA

BODIPY FL Forskolin
BODIPY FL Histamine

BODIPY FL Prazosin

MRP1

BCRP

Lasalocid

Loxapine

Nicardipine

Lasalocid

Mometasone
Nicardipine
Loxapine

Pimozide
Verapamil
Mometasone

Pimozide
Verapamil
Nicardipine

Mometasone

Pimozide

Nicardipine
Mometasone
Nicardipine
Nicardipine

Lasalocid

Nicardipine

Mometasone
Nicardipine
Pimozide

Mometasone

Pimozide
Verapamil
Loxapine

Verapamil

Nicardipine

Mometasone

Verapamil
Nicardipine

Mometasone
Nicardipine
Mometasone

Pimozide
Nicardipine

Mometasone

Pimozide

Loxapine
BODIPY FL
Thapsigargin
BODIPY FL Verapamil,
HCl

Mometasone

Loxapine

Loxapine

Nicardipine

Verapamil

Mometasone

Loxapine

Pimozide

Loxapine

Pimozide

Mometasone

Verapamil

Mometasone

Verapamil

Nicardipine
BODIPY FL Vinblastine
Calcein AM
CBIC2(3) (JC-1)
CellTracker Orange
CMTMR
DiIC1(5)

DiNOC1(3) (JC-9)

Nicardipine

Mometasone

Loxapine

Mometasone

Nicardipine

Verapamil

Nicardipine

Mometasone

XR9576

MK-571

Nicardipine

Nicardipine

Pimozide

Mometasone

Pimozide

Mometasone

Pimozide

Mometasone

Pimozide

Nicardipine

Nicardipine

Mometasone

Pimozide

Nicardipine

Nicardipine

Verapamil

Verapamil

Mometasone

Pimozide

Mometasone

Nicardipine
Mometasone

Pimozide

Mometasone

Pimozide

Nicardipine

Verapamil

Nicardipine

Verapamil

Loxapine

Mometasone

Pimozide

Mometasone

Pimozide

Nicardipine

Verapamil

Nicardipine

Verapamil

Pimozide

Mometasone

Loxapine
DiOC5(3)
DiOC6(3)

DiSC3(5)

Nicardipine

Pimozide

Loxapine
DiOC2(3)

Verapamil

Mometasone

Loxapine

Nicardipine

Verapamil

Pimozide

Mometasone

Pimozide

Pimozide

Nicardipine

Verapamil

Verapamil

Mometasone

Pimozide

Mometasone

Nicardipine

Verapamil

Loxapine
Doxorubicin

Substrate

Substrate

Substrate
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eFluxx-ID Gold

Substrate

Substrate

Substrate

eFluxx-ID Green

Substrate

Substrate

Substrate

Mometasone

Nicardipine

Nicardipine

Pimozide

ER-Tracker Green

LDS 751

Mometasone

Pimozide

Nicardipine

Verapamil

Loxapine

MitoTracker Green FM

Mometasone

Pimozide

Mometasone

Nicardipine

Verapamil

Nicardipine

Loxapine
MitoTracker Orange
CMTMRos
Mitoxantrone

Mometasone

Verapamil
Pimozide

Nicardipine
Substrate

Substrate

Ko143
FTC

Pheophorbide A
Rhodamine 123
Rhodamine 6G chloride
Rhodamine B, hexyl
ester, perchlorate (R6)

SYTO 13

Substrate
PSC833
Mometasone
Nicardipine
Mometasone

Pimozide

Mometasone

Pimozide

Mometasone

Pimozide

Mometasone

Pimozide

Nicardipine

Verapamil

Nicardipine

Verapamil

Nicardipine

Loxapine
SYTO 16
SYTO 9
Tetramethylrosamine
Chloride
TMRE

Mometasone

Loxapine
Pimozide

Pimozide

Pimozide

Mometasone

Pimozide

Mometasone

Nicardipine
Mometasone
Nicardipine
Mometasone
Nicardipine
Mometasone
Nicardipine

Verapamil

Nicardipine
Pimozide

Verapamil

GF120918
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APPENDIX B
Radioactive substrates of ABC Transporters
P-gp

MRP1

MRP2

MRP3

MRP4

BCRP

[ring C,
methoxy-3H]Colchicine

[14C]-1-Chloro2,4Dinitrobenzene
([14C]-CDNB)

[14C]-1Chloro-2,4Dinitrobenzene
([14C]-CDNB)

[6,7-3H]
Estradiol 17(β-dGlucuronide)
([3H]-E217βG)

[3H] Estradiol 17(β-d-Glucuronide)
([3H]-E217βG)

[3H]Daunorubicin

[3H]Daunorubicin

[3H]-Docetaxel

[6,7-3H]
Estradiol 17(β -dGlucuronide)
([3H]-E217βG)
[3’,5’,7’3
H(n)]Methotrexate

[G-3H]Digoxin

[6,7-3H]
Estradiol 17-(βd-Glucuronide)
([3H]-E217βG)
[3H]Leukotriene C4
([3H]-LTC4)

[3H]-Etoposide

[3H]-Mitoxantrone

[6,7-3H]
Estradiol 17(β-dGlucuronide)
([3H]-E217βG)

[14C]-2-Amino-1Methyl-6Phenylimidazo[4,5b]Pyridine ([14C]PhIP)

[3H]Paclitaxel

[7-methoxy3
H]-Prazosin
[3H]Vinblastine
[G-3H]Vinblastine
Sulfate

[3’,5’,7’3
H(n)]Methotrexate
[3H]-Paclitaxel
[3H]Vinblastine

[3H]-Methotrexate

